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ABSTRACT
Obesity is a metabolic disorder characterized by excess energy storage in adipose
tissue and it increases the risk for Type 2 diabetes. Impaired or altered adipocyte function
during obesity can contribute to metabolic dysfunction. DBC1 (deleted in breast cancer
1) and EHMTs 1 and 2 (euchromatic histone lysine methyltransferases 1 and 2) have
been shown to have a role in fat cell development and function. DBC1 is typically localized
in the nucleus and can regulate a variety of epigenetic modifiers, transcription factors,
and nuclear receptors. EHMTs 1 and 2, also known respectively as GLP and G9a, were
initially classified as histone methyltransferases that primarily function to catalyze monoand di-methylation of lysine 9 in histone H3 (H3K9), but more recent studies have shown
that these two proteins can methylate non-histone substrates and have the capacity to
function as transcriptional co-activators independent of their methyltransferase activity.
Although there have been advancements in demonstrating the importance of these
proteins in metabolic disease, the underlying mechanisms of DBC1, G9a, and GLP in
adipocytes that contribute to the pathogenesis of obesity and Type 2 diabetes are largely
unknown. To further understand how DBC1, G9a, and GLP expression in adipocytes
contributes to metabolic health, we utilized siRNA-mediated knockdown approaches to
determine if loss of these proteins in adipocytes could perturb the action of TNFα, a proinflammatory cytokine typically upregulated in obesity and Type 2 diabetes. Although
DBC1 knockdown did not have a profound effect on TNFα-regulated gene expression,
we observed that loss of DBC1 increased Glut4 mRNA expression and reduced TNFαinduced lipolysis, a phenotype likely to be metabolically favorable in adipocytes.
Conversely, we demonstrated that simultaneous knockdown of G9a and GLP enhanced
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TNFα’s ability to transcriptionally activate pro-inflammatory gene expression and induce
lipolysis, a phenotype that could be considered metabolically unfavorable in fat cells.
These studies provide novel insight on the contributions of DBC1, G9a, and GLP to
adipocyte gene expression and function that is associated with metabolic health. Overall,
these findings advance our understanding of adipocyte-autonomous roles for DBC1, G9a,
and GLP that potentially contribute to the pathogenesis of obesity and Type 2 diabetes.
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CHAPTER 1. GENERAL INTRODUCTION
1.1. Adipose tissue structure and function
For centuries, adipose tissue (AT) was thought to solely function as an inert
storage depot for lipid. However, studies over the past three decades have established
AT as an intricate multi-function organ that has a fundamental role in the regulation of
systemic metabolic homeostasis, physiology, and pathophysiology. AT is often
considered the largest endocrine organ and AT endocrine functions affect the activity of
cells and tissues throughout the body. AT contributes to numerous physiological
processes including energy expenditure, lipid metabolism, glucose homeostasis, insulin
sensitivity, appetite, angiogenesis, blood pressure, and inflammation (Rajala & Scherer
2003; Rosen & Spiegelman 2006; Athyros et al. 2010).
AT is compartmentalized into individual depots that are distributed throughout the
body. There are major developmental and functional differences between individual
depots. The adipose tissue organ in humans primarily consists of white adipose tissue
(WAT), but there is also evidence that adult humans have some brown adipose tissue
(BAT) (Nedergaard et al. 2007; Cypess et al. 2009). WAT consists of subcutaneous (SAT)
and visceral adipose tissue (VAT). The majority of SAT is found below the skin in the
abdominal and gluteofemoral regions (Figure 1.1). VAT surrounds the inner organs and
is further classified into omental, mesenteric, retroperitoneal, gonadal, and pericardial
depots. BAT is secluded to the subscapular and supraclavicular regions.
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Figure 1.1. Fat depot distribution in humans. White adipose tissue (WAT) is found in
subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT). SAT depots
(green arrows) include abdominal and gluteofemoral. VAT depots (red arrows) include
pericardial, omental, retroperitoneal, mesenteric, and gonadal. Brown adipose tissue
(BAT) depots (blue arrows) include subscapular and supraclavicular.
AT is comprised of a variety of cell types that include adipocytes, preadipocytes,
endothelial cells, adipocyte progenitor cells, macrophages, and other immune cells.
Adipocytes are highly specialized and the predominant cell type in AT. They are generally
classified as white or brown adipocytes. White adipocytes are characterized by a large
unilocular fat droplet with a displaced nucleus. The three major functions of white
adipocytes include: 1) store and release lipid/fatty acids (FAs) 2) insulin-stimulated
glucose uptake and 3) secrete adipokines, lipokines, cytokines, and exosomal miRNAs
that can act in a paracrine or endocrine manner (Ezaki 1989; Yore et al. 2014; Thomou
et al. 2017; Scheja & Heeren 2019). Conversely, brown adipocytes are characterized by
multilocular fat droplets and have high mitochondrial content. The primary function of
brown adipocytes is non-shivering thermogenesis, which is largely mediated by the action
2

of a protein found in the inner mitochondrial membrane known as uncoupling protein-1
(UCP1) (Ikeda et al. 2018). UCP1 uncouples the proton gradient from ATP synthesis to
generate heat (Nedergaard et al. 2001). Brown adipocytes also have endocrine functions
and studies over the past few years have aimed to identify batokines (Villarroya et al.
2017). Recent evidence has also identified a new thermogenic fat cell type known as
beige adipocytes. Similar to brown adipocytes, beige adipocytes have multilocular lipid
droplets, high mitochondrial content, and express UCP1 (Ikeda et al. 2018). Studies have
suggested that cold exposure, exercise, and peroxisome proliferator activated receptor
gamma (PPAR) agonists induce beiging in sWAT (Ikeda et al. 2018).
Adipocytes secrete a variety of hormones that have an effect on whole-body
metabolism. The paradigm-shifting discovery of leptin in 1994 led to the recognition of
adipocytes as bonafide endocrine cells. Dr. Friedman’s lab showed that adipocytes
secrete leptin into circulation and have profound impact on appetite regulation (Zhang et
al. 1994; Halaas et al. 1995). Shortly after, adiponectin was the second fat-specific
hormone discovered (Scherer et al. 1995; Hu et al. 1996; Maeda et al. 1996). Adiponectin
has been shown to act on adipose tissue, skeletal muscle, liver, heart, and pancreas to
improve metabolic health by enhancing insulin sensitivity and reducing inflammation
(Ruan & Dong 2016). Conversely, adipocytes secrete resistin, a hormone that is involved
in the pathogenesis of insulin resistance. Resistin has been shown to have a negative
impact on metabolic health by impairing insulin action and sensitivity in fat, muscle, and
liver (Steppan et al. 2001) In humans, studies have shown that resistin is largely secreted
from monocytes and macrophages in AT rather than adipocytes (Schwartz & Lazar 2011).
However, the function of resistin in mouse and man is the same (Qatanani et al. 2009).

3

In addition to classical protein hormones, AT synthesizes and secretes
microRNAs, which are 19-22 nucleotide non-coding RNAs that can be found in circulating
exosomes and can regulate gene expression in distant tissues. miRNAs have a role in fat
cell development, lipid and glucose metabolism, and endocrine function (Xie et al. 2009;
Castaño et al. 2018). Interestingly, studies in mouse and human have demonstrated AT
is the principal source of exosomal miRNAs in circulation and each AT depot secretes
different exosomal miRNAs (Thomou et al. 2017). Specific miRNAs in AT have been
implicated in obesity and Type 2 diabetes (T2D) (Trajkovski et al. 2011; Arner et al. 2012;
Arner & Kulyté 2015). Studies have also shown that miRNAs in WAT substantially
decrease with age due to reductions in Dicer, the miRNA processing enzyme (Mori et al.
2012). Overall, miRNAs have a significant role in regulating important physiological
functions and recent studies are aimed to determine if targeting miRNAs in AT could treat
metabolic disorders.
Recently, a novel class of signaling lipids known as palmitic-acid-9-hydroxystearic-acid (PAHSAs) have been shown to exert metabolically beneficial effects.
Although PAHSAs are present in several tissues, they are predominantly found in WAT
and BAT (Yore et al. 2014). PAHSA levels highly correlate with insulin sensitivity in
humans as PAHSA levels in circulation and SAT are lower in insulin-resistant compared
with insulin-sensitive individuals (Yore et al. 2014). Initial mechanistic studies showed that
PAHSAs activate G-protein-coupled receptors (GPCR) and GPR120 mediates the effects
of PAHSAs to enhance insulin-stimulated glucose uptake in adipocytes. PAHSAs have
also been shown to decrease AT inflammation through reduction of pro-inflammatory
macrophages (Yore et al. 2014). PAHSAs do not have an effect on adiposity, but there is
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evidence that these bioactive lipids enhance glucose tolerance and insulin sensitivity in
mice fed either a chow diet or high fat diet (HFD) (Syed et al. 2018). Both acute and
chronic PAHSA treatment enhanced insulin’s ability to suppress endogenous glucose
production in chow- and HFD-fed mice. Notably, there is evidence that PAHSAs enhance
insulin’s ability to suppress lipolysis in vivo and have the ability to suppress lipolysis in
WAT explants (Zhou et al. 2019). Overall, these studies suggest that PAHSAs could be
associated with improvements in metabolic health.
1.2. The role of adipose tissue in metabolic disease
Excess energy storage in AT leads to obesity, which is a multifactorial disease that
is a major risk factor for the development of Type 2 diabetes (T2D), cardiovascular
disease (CVD), hypertension, and several types of cancer (Lauby-Secretan et al. 2016;
Gadde et al. 2018). Obesity has become a worldwide epidemic and affects approximately
39.8% of adults in the United States. Obesity is classically defined by a body mass index
(BMI) of 30 or greater. However, the metabolic complications associated with obesity are
largely determined by body fat distribution. In humans, white adipose tissue (WAT)
consists of SAT depots that can be metabolically protective and VAT depots that are
typically associated with insulin resistance (Chusyd et al. 2016). Evidence suggests that
individuals with gynoid obesity (pear-shaped body) have more subcutaneous fat in the
gluteofemoral region and less risk for developing metabolic syndrome (Chusyd et al.
2016). Studies in humans have demonstrated the gluteofemoral depot has lower
triglyceride content, higher levels of high-density lipoprotein (HDL) cholesterol, secretes
more beneficial hormones and produces less pro-inflammatory cytokines. On the
contrary, individuals with android obesity (apple-shaped body) have more visceral fat and
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greater risk for developing metabolic syndrome (Kwon et al. 2017). Symptoms of
metabolic

syndrome

include

abdominal

obesity,

hypertension,

hyperglycemia,

hyperlipidemia, and decreased HDL levels. In general, obese individuals that exhibit
characteristics such as insulin sensitivity, healthy AT expansion, metabolic flexibility,
increased circulating adiponectin, and decreased systemic inflammation are considered
to be metabolically healthy obese (MHO) (Samocha-Bonet et al. 2014). Studies over the
past few decades have aimed to determine underlying mechanisms that contribute to
decreased basal lipolysis and unrestrained expansion of subcutaneous fat depots in
metabolically healthy obese individuals (Stefan et al. 2013).
AT can expand via hypertrophy or hyperplasia. Hypertrophy occurs when existing
adipocytes in AT increase in size (Figure 1.2). It is characterized by inflammation, insulin
resistance, hypoxia, elevated lipolysis, and reduced secretion of adiponectin, which are
associated with metabolically unhealthy obesity. Hyperplasia occurs when resident
preadipocytes differentiate into new mature adipocytes (Figure 1.2). It is characterized by
increased vascularization and circulating adiponectin and typically associated with
metabolically healthy obesity. Development of the doxycycline-inducible AdipoChaser
mouse, an inducible adipocyte-tagging system, has demonstrated the adipogenic
capacity of different white adipose tissue depots under diet-induced obesity (DIO)
conditions and show that new adipocytes can develop from preadipocytes and contribute
to expansion of AT (Wang et al. 2013). Considering adipose tissue expansion through
adipogenesis has the potential to counterbalance the negative metabolic effects
associated with obesity, current research has been focused on investigating mechanisms
that promote adipogenesis rather than adipocyte hypertrophy.

6

Figure 1.2. Characteristics of healthy and unhealthy adipose tissue expansion. Healthy
AT expansion is characterized by adipocyte hyperplasia, increased vascularization,
insulin sensitivity, and a relatively anti-inflammatory state. Unhealthy AT expansion is
characterized by adipocyte hypertrophy, decreased vascularization, insulin resistance,
and a relatively pro-inflammatory state.
Unhealthy adipose tissue expansion can result in AT Inflammation, which is known
to induce insulin resistance. Resident macrophages in lean AT consists of M2-like
macrophages are relatively anti-inflammatory (Figure 1.2). However, in obese AT, there
is increased infiltration of macrophages that are predominantly M1-like macrophages that
form crown-like structures and promote inflammation and insulin resistance (Figure 1.2).
This is characterized by increased secretion of pro-inflammatory cytokines, chemokines,
and hormones including monocyte chemoattractant protein-1 (MCP1), interleukin-6 (IL6), tumor necrosis alpha (TNFα), interleukin-1β (IL-1β) and resistin (Chin et al. 1996;
Steppan et al. 2001; Fain et al. 2004; Bruun et al. 2005; Nov et al. 2013). Obese AT is
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also associated with decreased circulation of the hormone, adiponectin (Arita et al. 1999;
Ouchi & Walsh 2007). Inflammation can change the way adipocytes respond to insulin
and consequently affects several metabolic pathways in adipocytes including glucose
uptake, lipolysis, and lipogenesis.
Much attention has be given to the effects of white adipose tissue heterogeneity
on metabolic health. Remarkably, it has even been debated that anatomically distinct fat
depots should be regarded as separate organs considering each depot has
heterogeneous adipocyte populations that arise from distinct embryonic precursors. The
heterogeneity of WAT is influenced by developmental origin, metabolism, inflammation,
thermogenesis, and angiogenesis. Previous studies have demonstrated that individual
adipocytes in a single WAT depot may differ in insulin-stimulated glucose uptake,
lipogenic rate, response to catecholamines, and FFA uptake (Varlamov et al. 2015; Lee
et al. 2017). The most recent study published from Dr. Ronald Kahn’s lab used the
Immortomouse and lineage tracing analysis to show there are distinct white adipocyte
subpopulations within a single WAT depot that differ in gene expression profiles,
metabolism, and their response to cytokines/hormones (Lee et al. 2019). This study adds
another layer of complexity to adipocyte biology and is another factor that potentially
contributes to the development of risk factors associated with obesity.
1.3. JAK-STAT signaling pathway in adipocytes
The Janus kinase-signal transducer and activators of transcriptions (JAK-STAT)
signaling pathway consists of receptor-associated Janus kinases (JAKs), signal
transducers and activators of transcription (STATs), and a cytokine/hormone receptor that
lacks enzymatic activity (Mullen & Gonzalez-Perez 2016). In mammals, four members of
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the JAK family have been identified: JAK1, JAK2, JAK3, and Tyrosine kinase 2 (TYK2),
and seven members of the STAT family: STATs 1, 2, 3, 4, 5A, 5B, and 6 (Yamaoka et al.
2004). All STAT members are comprised of a helical N-terminal domain (ND), a coiled
coil (CC) domain, a DNA-binding domain (DBD), a helical linker (LK), a Src-homology 2
(SH2) domain, and a transactivation domain (TAD) located in the C-terminus region. JAK
is activated by the binding of ligands including growth factors, hormones, and cytokines
to their specific receptors. Upon ligand binding to the receptor, JAKs tyrosinephosphorylate themselves as well as the receptor (Harrison et al. 1998), creating a
cytosolic binding site for the SH2-domain of STAT proteins. The STATs are then activated
by JAKs via tyrosine phosphorylation in the TAD (Harrison et al. 1998; Rawlings et al.
2004). As shown in Figure 1.3, the activated STATs undergo dimerization via their Ntermini and translocate to the nucleus of the cell where the DNA-binding domain
recognizes specific promoter regions of DNA that results in either transcriptional
activation or repression (Rawlings et al. 2004).
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Figure 1.3. JAK-STAT signaling pathway in adipocytes. Upon phosphorylation of the
receptor and JAK kinase, a STAT protein associates with the receptor where it is activated
by JAK. Upon STAT tyrosine phosphorylation, active STATs form a dimer and translocate
to the nucleus where they modulate transcription.
To date, studies have shown that the only JAKs and STATs expressed in adipocytes
include JAK1, JAK2, STAT1, STAT3, STAT5A, STAT5B, and STAT6. It has been wellestablished that STAT proteins have cell-specific functions. Over the past two decades,
in vitro and in vivo studies have demonstrated STAT5 has a profound role in adipogenesis
and fat cell function. Initial studies showed STAT5 protein expression is greatly induced
during differentiation of 3T3-L1 preadipocytes and primary human subcutaneous
preadipocytes (Stephens et al. 1996; Harp et al. 2001). Furthermore, ectopic expression
of STAT5A promotes adipogenesis in non-precursor cells and 3T3-L1 preadipocytes
(Floyd & Stephens 2003a; Stewart et al. 2004). Athymic mice injected with STAT5Aexpressing fibroblasts resulted in the formation of ectopic fat pads suggesting that
STAT5A regulates adipose tissue development in vivo (Stewart et al. 2011a) .
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STAT5 proteins can be activated by a number of different cytokines/hormones,
but current evidence suggests that STAT5 proteins are primarily activated by growth
hormone (GH), a hormone secreted by the anterior pituitary gland that regulates fat mass
and insulin sensitivity. Several STAT5 target genes regulated by GH have been identified
including acyl-CoA oxidase (Aox), adipocyte protein 2 (Ap2; also known as fatty acid
binding protein 4 (Fabp4)), adiponectin (Adpn), B-cell lymphoma 6 (Bcl6), cytokineinducible

SH2-containing

protein

(Cish), fatty

acid

synthase

(Fas), pyruvate

dehydrogenase kinase 4 (Pdk4), suppressor of cytokine signaling-2 (Socs2),

and

suppressor of cytokine signaling-3 (Socs3) (Richter et al. 2003; Hogan & Stephens 2005;
Coulter & Stephens 2006; Barclay et al. 2007; White et al. 2007, 2016; Lin et al. 2014).
Although these target genes encode for proteins that are important for lipid
metabolism, glucose regulation, and insulin sensitivity, very little is known about the
molecular mechanisms that contribute to the ability of STAT5A to regulate gene
expression in adipocytes. To provide insight into the function of STAT5 in adipocytes, a
non-biased co-immunoprecipitation and mass spectrometry method was employed to
identify STAT5 interacting proteins in adipocytes. Pyruvate dehydrogenase complex-E2
(PDC-E2) was the first interacting protein reported from using this approach and
chromatin immunoprecipitation (ChIP) experiments revealed that PDC-E2 is bound to a
STAT5-binding site in the promoter of the STAT5 target gene, Cish (Richard et al. 2017).
Another protein identified was deleted in breast cancer 1 (DBC1), which will be discussed
later in this introduction.
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1.4. NF-κB signaling pathway in adipocytes
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) family
is comprised of five family members including p65 (RelA), RelB, c-Rel, p50, and p52,
which all share an N-terminal Rel homology domain (RHD) responsible for dimerization
and DNA binding. NF-κB family members are able to form homodimers and heterodimers.
The classical dimers are p65/p50 and p52/RelB. p65, RelB, and c-Rel contain a
transactivation domain (TAD) that functions to activate gene expression. p50 and p52
typically repress gene expression unless they bind to a protein that contains a TAD.
NF-κB has a fundamental role in regulating multiple biological functions including
inflammation, immunity, cell proliferation, and apoptosis. In the canonical pathway, NFκB proteins are sequestered in the cytoplasm and inhibited by inhibitor of NF-κB (IκB)
proteins under basal conditions. As shown in Figure 1.4, upon stimulation, IκB proteins
are phosphorylated. Phosphorylation of IκB results in the dissociation from NF-κB,
ubiquitination, and proteasomal degradation. NF-κB proteins are further activated by posttranslational modifications such as phosphorylation. Active NF-κB proteins then
translocate to the nucleus to regulate gene expression (as reviewed in Zhang et al. 2017).
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Figure 1.4. NF-κB signaling pathway in adipocytes. Upon ligand binding receptor, IκB
proteins are phosphorylated. Phosphorylation of IκB results in the dissociation from NFκB, ubiquitination, and proteasomal degradation. NF-κB proteins are phosphorylated and
translocate to the nucleus to regulate gene expression.
NF-κB can be activated by a variety of pro-inflammatory cytokines including tumor
necrosis factor alpha (TNFα) and interleukin-1β (IL-1β), as well as lipopolysaccharide
(LPS). TNFα is produced and upregulated in AT macrophages in conditions of
obesity/T2D and acts in a paracrine manner on adipocytes. TNFα perturbs the major
metabolic pathways in adipocytes including insulin-stimulated glucose uptake, lipolysis,
and lipogenesis. Furthermore, it is well-established that TNFα can induce insulin
resistance in adipocytes through alterations in gene/protein expression, impairment of
insulin signaling, and induction of lipolysis (Ruan et al. 2002a). TNFα transcriptionally
represses proteins involved in insulin-stimulated glucose uptake in adipocytes including
insulin receptor (IR), insulin receptor substrate-1 (IRS-1) and glucose transporter GLUT4
(Stephens et al. 1997). Additionally, TNFα directly disrupts insulin signaling by inhibiting
phosphorylation of IR and IRS-1, which consequently blocks insulin action (Feinstein et
13

al. 1993; Hotamisligil et al. 1994). TNFα induces the expression of genes associated with
inflammation

including

lipocalin-2

(Lcn2),

interleukin-6

(Il6),

and

monocyte

chemoattractant protein 1 (Mcp1) (Libermann & Baltimore 1990; Ping et al. 1999; Zhao
et al. 2014). Additionally, TNFα represses the expression of adiponectin, an antiinflammatory hormone associated with insulin sensitivity (Fasshauer et al. 2002).
In addition to carbohydrate metabolism, TNFα also has a profound role in lipid
metabolism. Enhanced lipolysis increases circulating levels of glycerol/free fatty acids, a
clinical manifestation that is considered harmful and typically associated with
metabolically unhealthy obesity and insulin resistance (Arner & Rydén 2015). It is welldocumented that TNFα induces adipocyte lipolysis, but the underlying mechanism
remains to be elucidated. The induction of lipolysis by TNFα has been demonstrated in
3T3-L1 adipocytes and adipocytes isolated from human subcutaneous adipose tissue
(SAT) (Green et al. 2004; Rydén et al. 2004). Moreover, studies have suggested that NFκB signaling is essential for TNFα-induced lipolysis in primary human subcutaneous
adipocytes (Laurencikiene et al. 2007). Glycerol and free fatty acid release from
adipocytes is observed about 6 hours after TNFα treatment suggesting this process is
largely mediated by genomic effects.
1.5. DBC1
Deleted in breast cancer 1 (DBC1), also known as cell cycle and apoptosis
regulator 2 (CCAR2), was discovered in 2002 and initially recognized as a gene
homozygously deleted in human breast cancer (Hamaguchi et al. 2002). DBC1 is
multifunctional protein that modulates a variety of nuclear receptors and epigenetic
modifiers that have implications in apoptosis, metabolism, RNA splicing, and circadian
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cycle. DBC1 is comprised of an S1-like RNA binding domain, a nuclear localization signal
(NLS), a leucine zipper domain (LZ), a nucleoside diphosphate linked to X domain
(NUDIX), an EF-hand domain, and a coiled coil domain (CC). The CC domain is important
for nuclear receptor interactions whereas the LZ domain is important for the interaction
with SIRT1 and HDAC3 (Figure 1.5).

Figure 1.5. Structural and functional domains of murine DBC1. The S1-like RNA binding
domain is important for RNA binding. The NLS is important for nuclear localization. The
leucine zipper domain is important for SIRT1 and HDAC3 interactions. The Nudix domain
senses SIRT1 deacetylation products. The coiled coil domain is important for the
interaction with Rev-erbα.

To date, there is evidence to support that DBC1 regulates cellular metabolism and
is at the interface of metabolic disease, aging, and cancer. Over the past decade, DBC1
has been shown to regulate several epigenetic modifiers and nuclear receptors. DBC1
has been shown to interact and inhibit sirtuin 1 (SIRT1), a nicotinamide adenosine
dinucleotide (NAD)-dependent deacetylase (Kim et al. 2008; Zhao et al. 2008).
Considering SIRT1 is involved in a variety of cellular processes including regulation of
obesity-associated metabolic diseases, cancer, aging, and cellular senescence, it is not
surprising that research has been focused on the DBC1/SIRT1 interaction. Mice with
overexpression of SIRT1 were protected from HFD-induced glucose intolerance and
nonalcoholic fatty liver disease (Pfluger et al. 2008). Conditional DBC1 knockout mice
exhibit a similar phenotype as they become obese, but are protected from HFD-induced
liver steatosis and inflammation (Escande et al. 2010). In addition to SIRT1, DBC1
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negatively regulates other epigenetic modifiers including histone deacetylase 3 (HDAC3)
and suppressor of variegation 3-9 homolog 1 (SUV39H1) (Li et al. 2009; Chini et al. 2010).
DBC1 also regulates the stability and function of several nuclear receptors including
androgen receptor (AR), estrogen receptor alpha (ERα), estrogen receptor beta (ERβ),
and the circadian cycle regulator Rev-erbα (Fu et al. 2009; Koyama et al. 2010; Yu et al.
2011; Chini et al. 2013).
To date, most DBC1 studies have been performed in tumor cells and little is known
about the function of DBC1 in adipocytes. However, studies have shown that knockdown
of DBC1 in 3T3-L1 preadipocytes promotes adipocyte development in vitro (MorenoNavarrete et al. 2015a). Also, DBC1 knockout mice have increased fat accumulation in
adipose tissue, but remain metabolically healthy (Escande et al. 2015). DBC1 knockout
mice maintained insulin sensitivity, had lower circulating free fatty acids, and were
protected against atherosclerosis and liver steatosis following diet induced obesity
(Escande et al. 2015). Other studies have shown that loss of DBC1 in 3T3-L1 adipocytes
results in decreased expression of inflammatory markers such as interleukin 6 (IL-6),
monocyte chemoattractant protein 1 (MCP1), and tumor necrosis factor alpha (TNFα),
indicating that DBC1 may influence adipocyte inflammation (Moreno-Navarrete et al.
2015). DBC1 has also been implicated in senescence of preadipocytes as loss of DBC1
protects again cellular senescence and senescence-driven inflammation in obesity
(Escande et al. 2014). Our lab has demonstrated that DBC1 is a novel STAT5Ainteracting protein in adipocytes (Able et al. 2018). However, we also observed that DBC1
interacts with other STAT proteins and nuclear receptors that are involved in adipocyte
development and function. Considering DBC1 interacts with a variety of transcription
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factors and nuclear factors, this could suggest that DBC1 functions as a general regulator
of transcription. RNAi knockdown approaches revealed loss of DBC1 expression in
adipocytes increased Glut4 expression and a reduction in glycerol/free fatty acid release
in DBC1-knockdown adipocytes under TNFα-stimulated conditions (Able et al. 2018).
Collectively, research from our laboratory and others indicates that loss of adipocyte
DBC1 results in a metabolically healthy phenotype.
1.6. G9a and GLP
G9a and GLP are lysine methyltransferases (KMTs) that are ubiquitously
expressed and share 42% amino acid homology. G9a and GLP have molecular weights
of 132 kD and 141 kD, respectively. Both proteins are localized in the nucleus and are
members of the SET domain-containing protein family, which is characterized by a 130
amino acid catalytic SET domain (Suppressor of variegation 3-9 (Su(var)3-9), Enhancer
of zeste (E(z)), and Trithorax (Trx) domain) (Herz et al. 2013). Interestingly, G9a and GLP
have the ability to form a heterodimeric complex via their SET domains and this interaction
has been reported to be required for their catalytic activity (Tachibana et al. 2005) (Figure
1.6). The SET domain in G9a and GLP are approximately 80% similar and is responsible
for catalyzing the transfer of a methyl group from the co-factor S-adenosyl-L-methionine
(SAM) to a substrate lysine (Tachibana et al. 2005). Embryonic stem cells obtained from
either G9a or GLP knockout mice had a robust reduction of mono- and di-methylation of
H3K9 suggesting that G9a and GLP are the primary methyltransferases for H3K9me1
and me2 in vivo (Tachibana et al. 2002, 2005). Moreover, G9a and GLP double knockout
mice did not further reduce mono- and di-methylation of H3K9 suggesting that G9a and
GLP cannot compensate for each other (Tachibana et al. 2005). When amino acids in the
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SET domain of G9a and GLP were mutated, only G9a SET domain mutants had
decreased H3K9 methylation suggesting that the lysine methyltransferase activity of G9a
is more important than GLP (Tachibana et al. 2008).
The SET domain is flanked by an N-terminal pre-SET domain and a C-terminal
post-SET domain. The pre-SET domain contains nine cysteine residues that coordinate
three zinc ions to form a triangular cluster, which has been shown to be important in
maintaining the protein structure (Mandal 2017). The post-SET domain contains three
cysteine residues that form a zinc binding site with a cysteine proximal to the catalytic site
of the SET domain and facilitates the binding of the co-factor S-adenosyl-L-methionine
(SAM) to the histone tail (Mandal 2017). Conserved tyrosine residues within the SET
domain of G9a and GLP have been shown to be imperative to the catalytic activity and
di-methyl H3K9 specificity (Wu et al. 2010). Specifically, Y1154 in G9a and Y1211 in GLP
is important for catalytic activity (Wu et al. 2010) and Y1067 in G9a and Y1125 in GLP is
responsible for hydrogen bonds to the nitrogen in the substrate lysine and dictates the
methylation state selectivity (mono- or demethylation) (Wu et al. 2010) (Figure 1.6).

Figure 1.6. Structural and functional domains of murine G9a and GLP and tyrosine
residues that are important for methyltransferase activity. The SET domain is important
for dimer formation and catalytic activity. The ankyrin repeats are important for proteinprotein interactions.
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Additionally, G9a and GLP contain contiguous 33 amino acid ankyrin repeats of
highly similar sequence that is upstream of the catalytically active SET domain (Collins et
al. 2008). The ankyrin repeats have been shown to have a role in protein-protein
interactions with histones and non-histone substrates (Collins et al. 2008; Ohno et al.
2013; Liu et al. 2015). Mutations in G9a and GLP ankyrin repeats revealed that the
ankyrin repeats in G9a and GLP recognize H3K9 and have high specificity for mono- and
dimethyl H3K9 (Collins et al. 2008), and their recognition of methylated lysines at specific
histone tail residues resembles the chromodomain, a well-known module found in
proteins involved in chromatin remodeling and transcriptional repression (Yap & Zhou
2011). Additionally, the ankyrin repeats of GLP have been shown to interact with PR
domain containing protein 16 (PRDM16) (Ohno et al. 2013). A recent study has shown
that mutations in the ankyrin repeats of GLP results in decreased H3K9 methylation and
suggest that the H3K9 binding activity of GLP is more important than G9a (Liu et al. 2015).
G9a and GLP have the ability to undergo automethylation at conserved lysine
residues near the N-terminus and is associated with protein-protein interactions. Studies
have shown that automethylation of K239 in murine G9a creates a binding site for
heterochromatic protein 1 (HP1) (Chin et al. 2007), which is a conserved chromatin
binding

protein

that

is

typically

associated

with

transcriptionally

repressed

heterochromatin (Zeng et al. 2010). G9a and GLP also have a glutamate-rich region
(consisting of 23 consecutive glutamate residues) and a cysteine-rich region, but the
functions of these regions remain to be elucidated.
Initially, proteins that contained a SET domain were thought to solely catalyze the
methylation of histones, but recent evidence has shown G9a and GLP can function as
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co-repressors and co-activators. G9a and GLP have the ability to be in co-repressor
complexes with DNA binding proteins and transcriptional repression requires the
methyltransferase activity of their SET domain (Győry et al. 2004; Nishio & Walsh 2004).
G9a and GLP also target many non-histone substrates including p50, p53, DNA
methyltransferase-1 (DNMT1), DNA methyltransferase-3 (DNMT3), histone deacetylase1 (HDAC1), sirtuin-1 (SIRT1), chromodomain Y-like protein (CDYL), apoptotic chromatin
condensation inducer in the nucleus-1 (ACIN1), Reptin, kruppel-like factor-12 (KLF12),
MyoD, and CCAAT/enhancer-binding protein- β (C/EBPβ) (Pless et al. 2008; Rathert et
al. 2008; Huang et al. 2010; Ea et al. 2012; Moore et al. 2013). Interestingly, G9a and
GLP can also function as co-activators for transcription factors and nuclear receptors,
activity such as p21 and glucocorticoid receptor (GR), independently of their
methyltransferase (Lee et al. 2006; Purcell et al. 2012; Oh et al. 2014). To date, the
underlying mechanisms of G9a/GLP mediated transcriptional regulation are largely
unknown. Early studies demonstrated that G9a and GLP were present in a complex with
zinc finger proteins, ZNF644 and Wiz, and suggested that these proteins guide the
G9a/GLP complex to specific promoters to repress gene expression (Ueda et al. 2006).
A recent study has shown that post-translational modifications of G9a/GLP are
responsible for their ability for this switch from co-repressor to co-activator (Poulard et al.
2017).
G9a and GLP are involved in a variety of cellular processes including cell
differentiation, regulation of plasticity, regulation of immune response, and tumor growth
(Shinkai & Tachibana 2011). However, G9a and GLP are most known for their critical
roles in tumorigenesis (Casciello et al. 2015; Rao et al. 2017) G9a and GLP are
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overexpressed in a variety of human cancers. The transcriptional activity of p53 is critical
for its tumor suppressor function. Studies show that G9a/GLP methylates and negatively
regulates p53, which consequently promotes tumor progression (Huang et al. 2010).
Under hypoxic conditions, G9a protein expression and activity increases resulting in an
increase in di-methylation of H3K9 and consequent silencing of hypoxia-responsive
genes (Chen et al. 2006). Additional studies demonstrated that G9a and GLP directly bind
and methylate the alpha subunit of hypoxia-inducible factor 1 (HIF-1α) which
subsequently represses its transcriptional activity (Bao et al. 2018). These studies
suggest G9a and GLP also have a role in the promotion of cell survival. Embryogenesis
is largely mediated by G9a and GLP’s H3K9 methyltransferase function. The first studies
demonstrated the requirement of G9a and GLP in mouse development, as global
depletion of G9a or GLP in mice resulted in embryonic lethality. This was the first study
to show G9a and GLP were required for the differentiation of embryonic stem cells.
Additionally, G9a and GLP are important for differentiation in a variety of other cell types
including adipocytes, T cells, cardiomyocytes, and neurons (Wang et al. 2012; Inagawa
et al. 2013; Antignano et al. 2014; Fiszbein et al. 2016).
To date, a few studies have demonstrated the importance of G9a and GLP in
metabolic health. The use of G9a inhibitors improved Prader Willi Syndrome (PWS), a
genetic condition that is characterized by GH deficiency, hypotonia, poor growth, and
childhood obesity, by upregulating PWS associated genes from the maternal
chromosome in both human PWS patient cells and in a PWS mouse model (Kim et al.
2017). Other studies have shown that G9a is downregulated in the liver of db/db mice
(Xue et al. 2018), an obese and diabetic mouse model that do not express a functional
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leptin receptor and exhibit insulin resistance. Interestingly, when G9a is overexpressed in
the db/db mice, hepatic insulin signaling is restored (Xue et al. 2018). Additional in vitro
experiments demonstrated that knockdown of G9a in hepatocytes resulted in reduced
expression of the insulin receptor and pAKT, and experiments using BIX-01294, a
G9a/GLP inhibitor that suppresses its catalytic function, had no effect on insulin receptor
and pAKT expression (Xue et al. 2018). Together, these studies proposed the idea that
G9a functions as a coactivator and is capable of modulating hepatic insulin signaling
independent of its methyltransferase activity.
Very few studies have been examined the function of G9a and GLP in adipocytes.
G9a adipocyte-specific knockout mice using the aP2 promoter resulted in upregulation of
adipogenic gene expression, increased adiposity, increased lipid accumulation in liver,
hyperinsulinemia, hyperleptinemia, and decreased levels of adiponectin in circulation
(Wang et al. 2012). Further mechanistic studies using cultured brown preadipocytes from
the G9a floxed mice demonstrated that G9a suppresses the master regulator of
adipogenesis, peroxisome proliferator activated receptor gamma (PPAR), through dimethylation of H3K9 on the PPAR promoter (Wang et al. 2012). Together, these studies
suggest that G9a suppresses adipocyte development through repression of PPAR. Dr.
Shingo Kajimura’s lab generated GLP adipocyte-specific knockout mice using the
adiponectin promoter (Ehmt1adipoKO) which revealed a reduction in BAT-mediated
thermogenesis. After 4 weeks of HFD, these mice exhibited an adiposity phenotype, as
observed by increased BAT and WAT mass. After 9 weeks of HFD, Ehmt1adipoKO mice
had decreased insulin sensitivity, no significant change in basal lipolysis compared to
wildtype mice, hyperinsulinemia, and ectopic lipid storage in liver (Ohno et al. 2013). All
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together these studies indicated that a loss of G9a or GLP in adipocytes results in a
metabolically unhealthy phenotype.
1.7 Research Focus
Approximately 93 million US adults are classified as obese. Obesity and its
associated metabolic disorders are typically accompanied by chronic inflammation.
Specifically, chronic inflammation in AT has a role in the pathogenesis of insulin
resistance (Saltiel & Olefsky 2017). However, some obese individuals are metabolically
healthy and exhibit characteristics such as insulin sensitivity, healthy AT expansion,
metabolic flexibility, increased circulating adiponectin, and decreased systemic
inflammation. Although recent studies have made advancements in demonstrating the
importance of epigenetic mechanisms in AT in the pathogenesis of metabolic disorders,
the function and underlying molecular mechanisms of DBC1, G9a, and GLP in AT has
not been widely investigated. To assess the potential role of DBC1, G9a, and GLP
expression in adipocytes contributing to metabolic health, we performed siRNA-mediated
knockdown of DBC1, G9a, or GLP in cultured murine adipocytes. We wanted to
determine if the loss of these proteins could disrupt TNFα’s regulation of metabolically
unhealthy gene expression in adipocytes. Our studies revealed that simultaneous
knockdown of G9a and GLP increased TNFα’s ability to induce pro-inflammatory gene
expression in adipocytes. On the other hand, loss of DBC1 expression had no effect on
TNF’s ability to regulate gene expression. Interestingly, DBC1, G9a, and GLP expression
modulates TNFα’s ability to induce lipolysis in adipocytes. Our studies revealed that loss
of DBC1 in adipocytes decreases TNFα’s ability to induce lipolysis whereas simultaneous
loss of G9a and GLP in adipocytes increases TNFα’s ability to induce lipolysis. These
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studies provide insight to the contributions of DBC1, G9a, and GLP expression on
adipocyte gene expression and function that is associated with metabolic health.
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CHAPTER 2. LOSS OF DBC1 (CCAR2) AFFECTS TNFα-INDUCED
LIPOLYSIS AND GLUT4 GENE EXPRESSION IN MURINE ADIPOCYTES
2.1. Introduction
Signal transducer and activators of transcription 5A (STAT5A) is a transcription
factor that utilizes the Janus Kinase/Signal Transducer and Activator of Transcription
(JAK/STAT) pathway to mediate the biological actions of a variety of hormones and
cytokines. In vivo and in vitro approaches have demonstrated that STAT5A has a
prominent role in adipogenesis (Teglund et al. 1998, Floyd & Stephens 2003, Stewart et
al. 2011a, Wakao et al. 2011, Tse et al. 2013). Growth hormone (GH) is a primary
activator of STAT5A in adipocytes. Upon GH activation, STAT5A can activate or repress
several genes including suppressor of cytokine signaling 3 (Socs3), cytokine-inducible
SH2-containing protein (Cish), B-cell lymphoma 6 (Bcl6), fatty acid synthase (Fasn),
Adiponectin, and pyruvate dehydrogenase kinase 4 (Pdk4) in adipocytes (Hogan &
Stephens 2005, Story & Stephens 2006, White et al. 2007, 2016, Lin et al. 2014). Despite
the identification of these direct STAT5 target genes, very little is known about the
molecular mechanisms that contribute to the ability of STAT5A to regulate gene
expression in adipocytes. To further investigate the functions of STAT5A in adipocytes,
we sought to identify novel proteins that interact with STAT5A by performing a non-biased
co-immunoprecipitation and mass spectrometry approach (Richard et al. 2017). This
approach identified DBC1 (deleted in breast cancer 1) as a potential STAT5A-interacting
protein.
This chapter previously appeared as Able AA, Richard AR, & Stephens JM Loss of DBC1 (CCAR2) affects
TNFα-induced lipolysis and Glut4 gene expression in murine adipocytes, Journal of Molecular
Endocrinology 2018. It is reprinted by permission of Bioscientifica Limited.
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DBC1, also referred to as CCAR2 (cell cycle and apoptosis regulator 2), is a
pleiotropic protein that is primarily localized in the nucleus. DBC1 has been shown to
physically interact and negatively regulate several epigenetic modifiers including sirtuin 1
(SIRT1), histone deacetylase 3 (HDAC3), and suppressor of variegation 3-9 homolog 1
(SUV39H1) (Zhao et al. 2008, Li et al. 2009, Chini et al. 2010). SIRT1 is a nicotinamide
adenine dinucleotide (NAD)-dependent deacetylase involved in a variety of cellular
processes including regulation of obesity-associated metabolic diseases, cancer, aging,
and cellular senescence (Rahman & Islam 2011). A loss of DBC1 expression is
associated with increased SIRT1 activity in A459 human alveolar basal epithelial cells
(Zhao et al. 2008). DBC1 also interacts and negatively regulates estrogen receptor β
(ERβ) and breast cancer 1 susceptibility protein 1 (BRCA1) (Hiraike et al. 2010, Koyama
et al. 2010). In addition, DBC1 can be present in a complex with and positively regulate
estrogen receptor α (ERα), androgen receptor (AR), and nuclear receptor subfamily 1,
group D, member 2 (Rev-erbα) (Fu et al. 2009, Yu et al. 2011, Chini et al. 2013). DBC1
has also been shown to physically interact with and positively regulate IKK-α and IKK-β;
two kinases that are part of the inhibitor of kappa B Kinase (IKK) complex that affects
nuclear factor kappa B (NF-κB) signaling and transcriptional activity (Kong et al. 2015).
To date, most DBC1 studies have been performed in tumor cells and little is known
about the function of DBC1 in adipocytes. However, studies have shown that knockdown
of DBC1 in 3T3-L1 preadipocytes promotes adipocyte development in vitro (MorenoNavarrete et al. 2015a). Also, DBC1 knockout mice have increased fat accumulation in
adipose tissue, but remain metabolically healthy (Escande et al. 2015). DBC1 knockout
mice maintained insulin sensitivity, had lower circulating free fatty acids, and were
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protected against atherosclerosis and liver steatosis following diet induced obesity
(Escande et al. 2015). Other studies have shown that loss of DBC1 in 3T3-L1 adipocytes
results in decreased expression of inflammatory markers such as interleukin 6 (IL-6),
monocyte chemoattractant protein 1 (MCP1), and tumor necrosis factor alpha (TNFα),
indicating that DBC1 may influence adipocyte inflammation (Moreno-Navarrete et al.
2015). DBC1 has also been implicated in senescence of preadipocytes as loss of DBC1
protects again cellular senescence and senescence-driven inflammation in obesity
(Escande et al. 2014).
Our studies are the first to show that DBC1 is present in a complex with STAT5A
under physiological conditions in the nucleus of adipocytes. However, knockdown
approaches revealed that DBC1 does not have a profound effect on the ability of growth
hormone to regulate STAT5 target genes. In studies to observe an impact of DBC1 loss
in adipocytes, we found that DBC1 can impact TNFα-mediated lipolysis in mature 3T3L1 adipocytes. Although, DBC1 did not have a profound effect on TNFα-mediated
changes in Mcp-1 or Adiponectin expression, the loss of DBC1 resulted in increased
Glut4 expression.
2.2. Materials and Methods
Cell culture
Murine 3T3-L1 preadipocytes (obtained from Dr. Howard Green at Harvard
University) were grown in Dulbecco’s Modified Eagle’s Media (DMEM) (Sigma-Aldrich,
St. Louis, MO) with 10% bovine calf serum. Two days after confluence, the preadipocytes
were induced to differentiate using a standard protocol and 3-isobutyl-methylxanthine,
dexamethasone, insulin (MDI) induction cocktail plus 10% fetal bovine serum (FBS) in
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DMEM (Richard et al. 2017). HyClone calf and fetal bovine serum were purchased from
Thermo Scientific (Waltham, MA) or GE Healthcare Life Sciences (Marlborough, MA).
The medium was changed every 48-72 hours during growth and differentiation. Cells
were serum deprived by changing the medium to DMEM containing 1% calf serum for 16
– 24 h before treatment with murine growth hormone (mGH) or murine TNFα.
Recombinant murine GH was obtained from Dr. A.F. Parlow at the National Hormone and
Peptide Program (NHPP; Torrance, CA). Recombinant murine TNFα was purchased from
Thermo Fisher (Waltham, MA; Cat #: PMC3013).
Small interfering RNA (siRNA)-mediated knockdown
3T3-L1 adipocytes (5-7 days post-MDI) were trypsinized and re-plated in 6-well,
12-well, or 24-well plates at a density of 5.8 x 105 cells/cm2 in antibiotic-free medium (10%
FBS/DMEM). Using the protocol from Dharmacon, adipocytes were transfected with 50
nM siRNA (Dharmacon, Lafayette, CO; Non-targeting siRNA Cat #: D-001810-10-50,
siRNA targeting DBC1 Cat #: L-047837-00-0005) and the DharmaFECT Duo reagent
(Dharmacon, Lafayette, CO, Cat #: T-2010-03) in OptiMEM reduced serum medium
(Thermo Fisher, Waltham, MA; Cat #: 31985088). Non-targeting siRNA was used as
negative control. After 24hrs, siRNA-containing media was removed, replaced with
antibiotic-free 10% FBS/DMEM, and cells were transfected again with 50 nM siRNA. After
24 hours, the media was removed and replaced with antibiotic-free 10% FBS/DMEM. Cell
monolayers were collected 72 hours following the initial transfection and harvested for
protein in immunoprecipitation (IP) buffer, and for RNA in buffer provided in the RNeasy
mini kit (Qiagen, Hilden, Germany) to assess knockdown efficiency. Knockdown of
Cyclophilin B was used as a positive control to assess siRNA transfection efficiency in
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3T3-L1 adipocytes because it is a well-characterized housekeeping gene that is not
affected by experimental treatments in adipocytes and has been validated in our lab.
(Dharmacon, Lafayette, CO; Cat #: D-001820-02-05).
RNA analysis
Adipocyte monolayers were harvested in lysis buffer from the RNeasy mini kit and
total RNA was isolated from harvested cells using the RNeasy mini kit (Qiagen, Hilden,
Germany). 10 µl of purified RNA was used for reverse transcription (RT) PCR to generate
cDNA according to the Applied Biosystems protocol (Applied Biosystems, Foster City,
CA; Cat #: 4368813). cDNA was quantitated using the real-time quantitative PCR (qPCR)
method in a total volume of 10 µl (2 µl DNA and 8 µl reaction master mix) using an Applied
Biosystems 7900HT Fast Real-Time PCR System and the qPCR amplification program
specified in the kit (Clontech, Mountain View, CA; Cat #: RR420A). Cyclophilin B,
Ubiquitin B, and Nono were used as endogenous controls. The following mouse genes
were examined by RT-qPCR: Cyclophilin b, Ubb, Nono, Dbc1, Socs3, Cish, Bcl6, Igf1,
Mcp1, Glut4, and Adiponectin using primers purchased from Integrated DNA
Technologies (IDT, Coralville, IA). Primer sequences for each gene are shown in Table
2.1.
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Table 2.1. Primer sequences for qPCR.

Whole cell extract preparation
Adipocyte monolayers were rinsed once with phosphate buffered saline (PBS) and
then harvested in non-denaturing IP buffer as previously described (Richard et al. 2017).
The cell extract was subjected to a freeze/thaw cycle at -80°C and then passed through
a 20-gauge needle three times. The whole cell extract was further purified by
centrifugation at 13,000 x g for 10 min at 4°C.
Subcellular fractionation
Mature 3T3-L1 adipocytes were treated with vehicle or murine growth hormone
prior to subcellular fractionation. Adipocyte monolayers from twenty 10-cm culture plates
were scraped into nuclear homogenization buffer (NHB) (20 mM Tris pH 7.4, 10 mM NaCl,
and 3 mL MgCl2) as previously described (Richard et al. 2017). After adding 0.15%
IGEPAL CA-630 (from 10% stock) to the cell suspension, it was homogenized on ice
using 16 strokes in a Dounce homogenizer. The extract was centrifuged at 2500 rpm in
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a Beckman GS-6KR centrifuge with a swinging bucket rotor. Subsequently, the
supernatant containing cytosol and mitochondria was centrifuged as previously described
(Richard et al. 2017). The nuclear pellet from the first centrifugation was washed once
with half of the initial volume of NHB buffer and re-centrifuged at 4°C for 5 min at 500 rpm
in the Beckman GS-6KR centrifuge. The supernatant was discarded, while the nuclear
pellet was resuspended in IP buffer and incubated on ice for 1 hour. To break open the
nuclei, the nuclear extract was passed through a 20G needle four times and further
purified by centrifuging at 13,000 x g for 10 min at 4°C.
Measurement of protein concentration
Protein content of cell extracts was quantified using the Bicinchoninic acid (BCA)
assay kit (Sigma-Aldrich, St. Louis, MO; Cat #: BCA1).
Gel electrophoresis and immunoblotting
Samples were separated on 7.5%, 10%, or 15% sodium dodecyl sulfate (SDS)
polyacrylamide (PA) gels (acrylamide; National Diagnostics, Atlanta, GA; Cat #: EC-890)
and transferred to nitrocellulose membranes (BioRad, Hercules, CA; Cat #: 162-0115) in
25 mM Tris, 192 mM glycine, and 20% methanol. After the transfer, the membrane was
blocked in 4% milk for 1 hour at room temperature and then immunoblotted. Results were
visualized with horseradish peroxidase-conjugated secondary antibodies (Jackson
ImmunoResearch, West Grove, PA) and enhanced chemiluminescence (Pierce/Thermo
Scientific, Waltham, MA).
Immunoprecipitation (IP)
Cell extracts (300–400 µg total protein) were incubated with 4-5 µg of
immunoprecipitating antibody, diluted in IP buffer, overnight on a mini-tube rotator at 4°C.
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Protein A-conjugated agarose beads (IPA300 Protein A Resin; Repligen, Waltham, MA;
Cat #: 10-2003-02) were added to the antibody-epitope mixture, and the conjugation
reaction proceeded for an additional 3-4 h at 4°C with rotation. Following conjugation to
the bead resin, the beads were pelleted by centrifugation at 13,000 rpm for 3 min at 4°C.
The supernatant was removed by aspiration and the beads were washed 3 times with ice
cold 1X IP buffer. Between each wash, the beads were pelleted by centrifugation at
10,000 rpm for 3 min at 4°C and the supernatant removed by aspiration. After the final
wash, the IP antibody and immunoprecipitated proteins were eluted from the bead resin
into 2X SDS loading buffer (LB) by boiling the samples for 10 min at 100°C. Samples
were flicked every 2 minutes during heat step to ensure efficient elution. The samples
were briefly centrifuged and the supernatants analyzed by SDS-PAGE and
immunoblotting. A mock sample containing only IP antibody and IP buffer (no cell extract)
was used as a negative control for each IP experiment.
SIRT1 activity measurement
The deacetylase activity of SIRT1 was measured using a fluorometric assay kit
(Enzo Life Sciences, Farmingdale, NY; Cat #: BML-AK500–0001). Cell extracts (75 µg
total protein) were incubated with 5 µg of anti-SIRT1 antibody using the
immunoprecipitation method described above. After the final wash, the samples were
resuspended in 100 μl of assay buffer provided by the assay kit. The manufacturer’s
instructions were followed and optimized for our samples. Briefly, the deacetylase
reaction was initiated by adding 50 µM of Fluor de lys® substrate and 1 mM nicotinamide
adenine dinucleotide (NAD+; SIRT1 substrate) to samples. After incubating the samples
for 20 minutes at room temperature, the reactions were stopped by addition of 1X Fluor

32

de lys® developer that contained either 1 µM trichostatin A (TricA; HDAC inhibitor) or 2
mM of nicotinamide (NAM ; SIRT1 inhibitor). Samples were read in a fluorometer
(SpectraMax M5) at an excitation wavelength of 360 nm and emission wavelength of 460
nm.
Measurement of glycerol and free fatty acid release
3T3-L1 adipocytes were transfected with either non-targeting or DBC1 siRNA as
described above. 54 hours later, media was changed to 1% calf/DMEM and cells were
treated with equivalent volume of vehicle (0.1% BSA/PBS) or 0.75 nM TNFα overnight.
After 16 hours, 1% calf/DMEM was removed and replaced with incubation media that
consisted of 2% fatty acid free bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO;
Cat #: A6003) and 0.1% glucose in glucose-free phenol red-free DMEM, and the cells
were treated again with vehicle (0.1% BSA/PBS) or 0.75 nM TNFα. After 2 hours, 500 μL
of conditioned media was collected and stored at -20°C. Glycerol release was measured
using 50 μL of each sample according to the kit protocol (Millipore, Burlington, MA; Cat
#: OB100). Free fatty acid release was measured using 50 μL of each sample according
to the kit protocol (BioVision, Milpitas, CA; Cat #: K612).
Antibodies
Anti-STAT5A (L-20; sc1081; rabbit polyclonal) and anti-ERK1/2 (C-16; sc-93;
rabbit polyclonal) antibodies were purchased from Santa Cruz Biotechnology (Dallas,
TX). We used both mouse monoclonal (clone 8-5-2; 05-495) and rabbit polyclonal (07586) anti-phospho-STAT5 A/B (Tyr 694/699) antibodies from Millipore (Burlington, MA)
to detect tyrosine phosphorylated STAT5 (STAT5pY). Anti-Adiponectin (PA1-054; rabbit
polyclonal) antibody was purchased from Thermo Scientific (Waltham, MA). Anti-DBC1
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(5693; rabbit polyclonal) and anti-SIRT1 (1F3; 8469; mouse monoclonal) antibodies were
purchased from Cell Signaling Technology (Danvers, MA).
Statistical analysis
All data were analyzed by two-tailed unpaired Student’s t-test (using GraphPad
Prism 7). Results from studies of cultured adipocytes are shown as mean ± standard error
of the mean (SEM). Results were considered statistically significant when p < 0.05.
2.3. Results
We previously utilized a semi-nonbiased screening approach to identify novel
STAT5 interaction partners using co-immunoprecipitation and mass spectrometry.
Pyruvate dehydrogenase complex-E2 (PDC-E2) was the first interacting protein that we
reported from this screen (Richard et al. 2017). In our present study, we report that DBC1
was also identified as a potential novel STAT5A-interacting protein in 3T3-L1 adipocytes.
To validate our mass spectrometry results, we performed co-immunoprecipitation with a
STAT5A antibody followed by Western blotting using an anti-DBC1 antibody and we
examined both cytosolic and nuclear extracts from mature 3T3-L1 adipocytes in the
absence or presence of an acute growth hormone (GH) treatment, a condition that
activates STAT5A (Figure 2.1A). These studies revealed that DBC1 interacts with
STAT5A in the nucleus and that the nuclear localization of DBC1, unlike STAT5A, was
not dependent on GH-induced STAT5 tyrosine phosphorylation (Figure 2.1A). To further
validate that these two proteins were present in the same protein complex in adipocytes,
we demonstrated that STAT5A could also be pulled down by a reverse coimmunoprecipitation using a DBC1 antibody (Figure 2.1B). Together, these experiments
corroborate that DBC1 is present in a complex with STAT5A under physiological
34

conditions in the nucleus of adipocytes and that this interaction is not dependent upon
GH stimulation or STAT5 tyrosine phosphorylation.

Figure 2.1. DBC1 is present in the nucleus of adipocytes and can be coimmnoprecipitated with STAT5A. (A) Fully differentiated 3T3-L1 adipocytes were treated
with 5 nM murine growth hormone (GH) or an equivalent volume of vehicle (10 mM
NaHCO3) for 20 minutes. Monolayers were collected and subjected to subcellular
fractionation. As shown in the left-hand portion of the figure, cytosolic and nuclear protein
extracts (300 μg total protein/sample) were immunoprecipitated (IP) with an anti-STAT5A
antibody. The mock sample contained anti-STAT5A antibody without cell extract. The
right-hand portion of the figure are direct western blot (WB) controls containing 75 μg total
protein that were directly subjected to Western blotting without IP. STAT5pY represents
phosphorylated STAT5 at tyrosine 694/699. This is a representative figure of an
experiment independently performed three times. (B) The monolayers of fully
differentiated 3T3-L1 adipocytes were harvested and whole cell protein extracts were
prepared. The left-hand portion of the figure shows IP of whole cell extract containing 400
μg of total protein, anti-DBC1 antibody, and IP buffer. Mock sample contained anti-DBC1
antibody without cell extract. The right-hand portion of the figure contains Western blot
controls. This is a representative figure of an experiment independently performed three
times on different groups of adipocytes.
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To assess the function of the DBC1/STAT5A interaction, we performed siRNA
experiments to knockdown DBC1 in mature adipocytes. The goal was to determine if
DBC1 expression had any effect on STAT5 phosphoactivation or transcriptional activity.
In these studies, we examined the ability of GH to induce STAT5A activation by
measuring STAT5A tyrosine phosphorylation. Western blot analysis showed that loss of
DBC1 levels did not have an effect on levels of STAT5A or STAT5pY (Figure 2.2).

Figure 2.2. Knockdown of DBC1 does not affect STAT5A protein expression or STAT5
tyrosine phosphorylation in 3T3-L1 adipocytes. Fully differentiated 3T3-L1 adipocytes
were transfected once per day for two days with non-targeting siRNA or DBC1 siRNA.
After 48 hours, adipocytes were serum deprived for 4 hours and treated with 5 nM murine
growth hormone (GH) or equivalent volume of vehicle (10 mM NaHCO3) for 20 minutes.
Monolayers were collected and 75 μg of total protein was separated using SDS-PAGE.
Protein expression was visualized using Western blotting with the antibodies indicated to
the left of panel. ERK was used as a loading control. Three biological replicates were
used for each treatment group in each individual experiment. This is a representative
figure of an experiment independently performed three times on different groups of
adipocytes.

To confirm that the loss of DBC1 protein affected its activity in adipocytes, we
performed additional experiments to measure SIRT1 activity. It is well established that
SIRT1 activity is negatively regulated by DBC1 (Kim et al. 2008, Zhao et al. 2008). As
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expected, our experiments showed an increase in SIRT1 activity when DBC1 protein
levels were reduced (*** p<0.001), suggesting that the knockdown of DBC1 also affected
its activity in adipocytes as judged by SIRT1 activity (Figure 2.3A). Induction of SIRT1
deacetylase activity in HeLa extract with the addition of nicotinamide adenine dinucleotide
(NAD+) or trichostatin A (TricA) was used as a control to confirm validity of the
deacetylase assay (Figure 2.3B).

Figure 2.3. Knockdown of DBC1 increases the deacetylase activity of SIRT1 in 3T3-L1
adipocytes. (A) SIRT1 deacetylase activity was measured in samples prepared by
immunoprecipitating SIRT1 from 3T3-L1 adipocytes transfected with non-targeting (NT)
or DBC1 siRNA. Each IP reaction contained 75 μg of total protein, anti-SIRT1 antibody,
and IP buffer. (B) HeLa extract was used as a control to assess SIRT1 deacetylase
activity. The graph shows the requirement of NAD+ for SIRT deacetylase activity and
Trichostatin A (TricA) inhibiting the Fluor de Lys® substrate deacetylation in HeLa nuclear
extract. Statistical significance was determined using a Student’s t-test and assigned as
*** p<0.001.

Tyrosine phosphorylated STAT5A can activate or repress the expression of many
genes. To determine if DBC1 expression had any effect on the transcriptional activity of
STAT5, we examined the expression of several STAT5 target genes following GH
treatment of mature adipocytes for 1 to 4 hours under control or DBC1-knockdown
conditions. The expression of STAT5A target genes (Socs3, Cish, and Bcl6) was
assessed by qPCR. It is known that Socs3 and Cish gene expression are highly induced
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one hour following STAT5 activation (Matsumoto et al. 1997, Karlsson et al. 1999, Barclay
et al. 2007), whereas Bcl6 gene expression is reduced following four hours of growth
hormone treatment (Lin et al. 2014). The data showed the expected regulation of Socs3,
Cish, and Bcl6 gene expression following one hour of growth hormone treatment.
However, there were no differences in mRNA levels of these genes in adipocytes with
reduced DBC1 expression (Figure 2.4). Similar results were observed for other STAT5A
target genes such as Adiponectin, Fasn, and Pdk4 (data not shown).

Figure 2.4. Knockdown of DBC1 in mature adipocytes does not affect the ability of GH to
alter the expression of STAT5A target genes. Fully differentiated 3T3-L1 adipocytes were
transfected once per day for two days with non-targeting (NT) siRNA or DBC1 siRNA.
After 48 hours, adipocytes were serum deprived for 4 hours and treated with 5 nM murine
growth hormone (GH) or equivalent volume of vehicle (V; 10 mM NaHCO3) for 1, 2, or 4
hours. Total RNA was isolated and subjected to quantitative RT-PCR analysis. Each
graph represents a different gene. The examined genes were normalized to Nono. This
is a representative figure of an experiment independently performed three times on
different groups of adipocytes.
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Although DBC1 did not have a profound impact on STAT5A transcriptional activity,
there is evidence in the literature that DBC1 may affect adipose tissue inflammation
(Moreno-Navarrete et al. 2015). We explored this on the cellular level by investigating the
ability of DBC1 to modulate TNFα action in adipocytes. TNFα is known to increase basal
lipolysis, promote the expression and secretion of pro-inflammatory cytokines, such as
IL-6, and reduce the secretion of anti-inflammatory hormones, such as adiponectin
(Berghe et al. 2000, He et al. 2016). To investigate the effects of DBC1 on TNFα action,
we used siRNA to knockdown DBC1 in mature 3T3-L1 adipocytes. Gene expression
analysis showed that a loss of DBC1, independent of TNFα treatment, increased Glut4
gene expression (***p<0.01 for Vehicle treatment and **p<0.01 for TNFα treatment) but
did not have a profound effect on TNFα-mediated changes in expression of Mcp1 or
Adiponectin (Figure 2.5A). Western blot analysis was used to assess the level of DBC1
protein knockdown and the effectiveness of TNFα treatment, as judged by reduced
adiponectin protein levels (Figure 2.5B), which was consistent with the changes observed
in Adiponectin gene expression (Figure 5A). We also assessed whether DBC1 expression
had an impact on TNFα-mediated lipolysis. Both free fatty acid and glycerol release were
measured from mature adipocytes following TNFα treatment in control and DBC1knockdown adipocytes. We observed a modest, but statistically significant, decrease in
TNFα-induced glycerol (*** p<0.005) and free fatty acid (* p<0.05) release with reduced
DBC1 expression (Figure 2.6).
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Figure 2.5. Knockdown of DBC1 in mature adipocytes results in increased Glut4 gene
expression but does not alter TNFα-mediated changes in gene expression. Fully
differentiated 3T3-L1 adipocytes were transfected once per day for two days with nontargeting (NT) siRNA or DBC1 siRNA. After 54 hours, media was replaced with 1% calf
and cells were treated with 0.75 nM TNFα overnight or equivalent volume of vehicle (0.1%
BSA/PBS). After 16 hours, cells were re-treated again with vehicle or TNFα for 2 hours.
Finally, monolayers were harvested for RNA and protein. (A) Total RNA was isolated and
subjected to quantitative RT-PCR analysis. The examined genes (each represented by
separate graph) were normalized to Nono. Statistical significance was determined using
a Student’s t-test and assigned as ** p<0.01, *** p<0.001, and **** p<0.0001. (B) 75 μg
of total protein was separated using SDS-PAGE. Protein expression was visualized using
Western blotting and the antibodies indicated on the left of panel. Three biological
replicates were used for each treatment group in each individual experiment. This is a
representative figure of an experiment independently performed three times on different
groups of adipocytes.

40

Figure 2.6. Knockdown of DBC1 in mature adipocytes modestly suppresses TNFαinduced lipolysis. Fully differentiated 3T3-L1 adipocytes were transfected once per day
for two days with non-targeting (NT) siRNA or DBC1 siRNA. After 54 hours, media was
replaced with incubation media and cells were treated with 0.75 nM TNFα or equivalent
volume of vehicle (0.1% BSA/PBS) overnight. After 12 hours, cells were treated again
with vehicle or TNFα for 2 hours. 50 μL of conditioned medium was used for free fatty
acid assay and glycerol assay. Statistical significance was determined using a Student’s
t-test and assigned as * p<0.05 and *** p<0.005. This is a representative figure of an
experiment independently performed two times on different groups of adipocytes.
2.4. Discussion
STAT5A is a transcription factor that can mediate the effects of growth hormone
(Zvonic et al. 2003) and promote adipocyte development (Floyd & Stephens 2003,
Stewart et al. 2011). In adipocytes, STAT5A regulates genes that contribute to insulin
sensitivity and the endocrine properties of adipocytes (Hogan & Stephens 2005, White et
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al. 2007, 2016). To further understand the mechanisms involved in the contribution of
STAT5A to fat cell function, we sought to identify novel STAT5A-interacting proteins in
adipocytes using a co-immunoprecipitation/mass-spectrometry approach. We recently
published data describing this approach and the identification of components of the
pyruvate dehydrogenase complex as STAT5A-binding proteins (Richard et al. 2017).
Another STAT5A-binding protein that we identified with this approach was the nuclear
protein, DBC1. DBC1 has been shown to mediate cellular responses to stress and
regulate the activity of a variety of enzymes and transcription factors in different cell types
(Joshi et al. 2013). Our novel observations demonstrate that DBC1 can be present in the
same protein complex as STAT5A in the nucleus of 3T3-L1 adipocytes (Figure 2.1). This
interaction was observed with endogenous proteins and could be detected by
immunoprecipitating either STAT5A or DBC1. In addition to this observation, our results
reveal that this interaction is not dependent on STAT5A tyrosine phosphorylation (Figure
2.1A).
To assess the potential function of the STAT5A/DBC1 association, we examined
STAT5A expression levels as well as STAT5A tyrosine phosphorylation in adipocytes that
had substantially decreased levels of DBC1. These studies revealed that loss of DBC1
did not alter STAT5A total protein levels or its ability to be activated, as judged by tyrosine
phosphorylation (Figure 2.2). We also examined the ability of STAT5A to regulate gene
expression in adipocytes with reduced DBC1 expression. To our surprise, there were no
profound changes in the expression of several STAT5A target genes in DBC1-deficient
adipocytes, which strongly indicates that DBC1 levels do not affect the transcriptional
activity of STAT5A (Figure 2.4). Although there were some modest differences in Socs3
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and Cish gene expression following 4 hour GH treatment in DBC1 knockdown adipocytes,
these results were not statistically significant. The effectiveness of siRNA-mediated DBC1
knockdown was assessed by examining gene and protein expression levels of DBC1
(Figures 2.2, 2.4, and 2.5) as well as SIRT1 deacetylase activity (Figure 2.3) since DBC1
is a well-known negative regulator of SIRT1 (Kim et al. 2008, Zhao et al. 2008, Liu et al.
2016). As expected, we observed an increase in SIRT1 activity, indicating that the activity
of DBC1 was likely altered in the DBC1-knockdown adipocytes (Figure 2.3). Presumably,
we only observed a modest increase in SIRT1 activity because DBC1 is only one of many
regulators of SIRT1 activity in mature adipocytes. Other studies have shown that a variety
of other factors including the cAMP/PKA pathway and AROS (active regulator of SIRT1)
can positively regulate SIRT1 (Kim et al. 2007, Chao & Tontonoz 2012). Collectively, our
observations suggest that DBC1 levels do not affect the transcriptional activity of
STAT5A.
Since there was evidence suggesting that DBC1 may have a pro-inflammatory role
in adipocytes by increasing the expression of NF-κB-regulated inflammatory cytokines
(Moreno-Navarrete et al. 2015), we examined the actions of TNFα on adipocytes with
reduced levels of DBC1. TNFα can induce insulin resistance, in part, through the
transcriptional repression of the Glut4 gene in adipocytes (Stephens & Pekala 1991,
Stephens et al. 1997, Ruan et al. 2002a) and by activating NF-κB (Ruan et al. 2002c). In
addition, TNFα can repress adiponectin gene expression in mouse and human
adipocytes (Fasshauer et al. 2002, Degawa-Yamauchi et al. 2005). Both increased
GLUT4 protein expression in adipocytes (Carvalho et al. 2005, Atkinson et al. 2013) and
increased adiponectin levels (Fu et al. 2005) are associated with improvements in insulin
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sensitivity. Knockdown of DBC1 did not alter TNFα-mediated induction of proinflammatory MCP-1 or repression of anti-inflammatory adiponectin (Figure 2.5A).
However, we consistently observed that a loss of DBC1 protein resulted in increased
Glut4 gene expression, which suggests a potential role for DBC1 in glucose regulation.
Studies in HepG2 cells have shown a knockdown of DBC1 results in the upregulation of
PEPCK (phosphoenolpyruvate carboxykinase) and consequently effects glucose
production (Nin et al. 2014). Experiments performed with inguinal fat tissue from DBC1null mice also showed increased PEPCK expression in DBC1-deficient tissue (MorenoNavarrete et al. 2015). Although additional experiments will be required to determine if
there are any direct effects of DBC1 on glucose metabolism or Glut4 gene expression,
our results suggest that DBC1 is a likely a negative regulator of GLUT4 in adipocytes
(Figure 2.5A).
Although the loss of DBC1 did not profoundly affect TNFα regulation of several
genes in adipocytes (Figure 2.5), we did observe that alteration of DBC1 levels affected
TNFα-induced lipolysis. Our studies revealed a modest but significant reduction in
glycerol and free fatty acid release in DBC1-knockdown adipocytes under TNFαstimulated conditions (Figure 2.6). This effect could be considered metabolically
favorable, which is also evident by the increased Glut4 expression we observed with loss
of DBC1. Overall, our observations are consistent with the phenotype of the DBC1knockout mice fed a high fat diet that are more insulin sensitive and have decreased
circulating FFA (Escande et al. 2015). Our data showing that loss of DBC1 increases
Glut4 expression and reduces TNFα-induced lipolysis suggests that the loss of DBC1 in
adipocytes may contribute to the metabolically protected phenotype of the DBC1 null

44

mice. Although additional experiments in adipocyte specific DBC1 knockout mice will be
needed, the current data are consistent with a role of DBC1 in promoting metabolic
dysfunction. Decreased FFA levels are typically associated with a metabolically healthy
phenotype. However, an increase in glycerol and fatty acids is often harmful and
associated with the clinical manifestations of metabolic syndrome, which also include
obesity and insulin resistance (Boden 1999, Arner & Rydén 2015). Our results show a
decrease in glycerol and free fatty acid release from TNFα-stimulated DBC1-deficient
adipocytes that occurs in a cell-autonomous manner and suggest that DBC1 plays a
direct or indirect role in the ability of TNFα to induce lipolysis.
Although these novel observations revealed that DBC1 is present in a protein
complex with STAT5A in adipocyte nuclei (Figure 2.1), most of our functional studies
reproducibly generated negative observations. The loss of DBC1 did not affect STAT5A
expression (Figure 2.2), STAT5A tyrosine phosphorylation (Figure 2.2), or the expression
of STAT5A target genes (Figure 2.4). Although DBC1 is clearly in a complex with STAT5,
and loss of DBC1 did result in expected increase in SIRT1 activity (Figure 2.3), we were
unable to perturb STAT5A expression, activation or activity. We did, however, have two
consistent effects that accompanied loss of DBC1 expression in adipocytes: 1) increased
Glut4 expression and 2) a statistically significant decrease in TNFα-induced lipolysis.
Nevertheless, it is unlikely that these functions of DBC1 are related to its interaction with
STAT5A. Further studies are needed to identify additional proteins present in the DBC1/
STAT5A complex, to elucidate the function of the DBC1/STAT5A interaction, and to
investigate the mechanism of DBC1’s ability to modulate TNFα-induced lipolysis.
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CHAPTER 3. LYSINE METHYLTRANSFERASES, G9A (EHMT2) and
GLP (EHMT1), AFFECT TNFα-REGULATED GENE EXPRESSION AND
LIPOLYSIS IN MURINE ADIPOCYTES
3.1. Introduction
G9a (also known as euchromatic histone methyltransferase 2; EHMT2) and GLP
(also known as euchromatic histone methyltransferase 1; EHMT1) primarily function to
catalyze mono- and di-methylation of lysine 9 of histone H3 (H3K9) using co-factor Sadenosyl methionine (SAM). Classically, mono-methylation of H3K9 is associated with
transcriptional activation and di-methylation at this site is associated with transcriptional
repression. Initially, studies indicated that G9a and GLP needed to form a heterodimeric
complex in order to exert their catalytic activity (Tachibana et al. 2002). However, recent
studies indicate that G9a and GLP have independent physiological functions (Liu et al.
2015; Xue et al. 2018), can methylate non-histone substrates (Rathert et al. 2008; Huang
et al. 2010), and can function as co-activators for a variety of nuclear receptors/
transcription factors independently of their methyltransferase activity (Lee et al. 2006;
Chaturvedi et al. 2009; Purcell et al. 2011; Rada et al. 2017; Xue et al. 2018).
Several studies have assessed the contribution of G9a and GLP expression in
relation to metabolic health. One study has shown that G9a is downregulated in the liver
of db/db mice (Xue et al. 2018), an obese and diabetic mouse model that does not
express the gene for the leptin receptor. Interestingly, when G9a is overexpressed in the
db/db mice, hepatic insulin signaling is restored (Xue et al. 2018). Additional in vitro
experiments demonstrated that knockdown of G9a protein levels in hepatocytes resulted
in reduced expression of the insulin receptor alpha (IRα) and phosphorylated AKT, and
experiments using a G9a/GLP specific inhibitor that suppresses its catalytic function, BIX46

01294, had no effect on IRα and pAKT expression (Xue et al. 2018). Together, these
studies proposed the idea that G9a functions as a co-activator and is capable of
modulating hepatic insulin signaling independent of its methyltransferase activity.
The function and underlying molecular mechanisms of G9a and GLP has not been
widely investigated in adipocytes. One study has shown mice with depleted G9a in
adipocytes

have

increased

adiposity,

increased

lipid

accumulation

in

liver,

hyperinsulinemia, and decreased adiponectin in circulation (Wang et al. 2012). Moreover,
experiments using primary brown preadipocytes from G9a floxed mice demonstrated that
G9a suppresses adipocyte development through repression of PPAR gene expression
(Wang et al. 2012). Another study revealed that adipocyte specific GLP knockout mice
have a reduction in brown adipose tissue (BAT)-mediated thermogenesis, increased
adiposity, decreased insulin sensitivity, increased circulating insulin, and increased liver
triglycerides (Ohno et al. 2013). Overall these studies demonstrate deletion of either G9a
or GLP expression in adipocytes promotes a metabolically unfavorable phenotype.
The regulation and function of G9a and GLP in white adipose tissue (WAT) in
conditions of obesity and T2D remains largely unknown so we became interested in
investigating how G9a and GLP impact adipocyte function and modulate gene expression
in white adipocytes. Considering G9a and GLP expression in adipocytes contributes to
metabolic health, we wanted to investigate if loss of G9a and GLP could disrupt tumor
necrosis factor alpha’s (TNFα) regulation of metabolically unhealthy gene expression in
adipocytes. TNFα is a pro-inflammatory cytokine produced and upregulated in adipose
tissue macrophages in conditions of obesity and T2D (Hotamisligil et al. 1995). Adipose
tissue TNFα acts in a paracrine manner on adipocytes and contributes to the development
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of insulin resistance through induction of lipolysis, impairment in insulin signaling, and
alterations in gene and protein expression (Cawthorn & Sethi 2008). TNFα promotes the
expression and secretion of other pro-inflammatory cytokines, such as interleukin-6 (IL6) (Libermann & Baltimore 1990). TNFα can also induce the adipokine, lipocalin-2
(LCN2), and the chemokine that contributes to macrophage infiltration into adipose tissue,
monocyte chemoattractant protein-1 (MCP1), which are both upregulated in obesity and
type 2 diabetes in mice and humans (Ueda et al. 1997; Ping et al. 1999). TNFα also
reduces expression and secretion of the fat specific hormone, adiponectin, and insulinregulated glucose transporter, GLUT4, which are both associated with insulin sensitivity
(Stephens et al. 1997; Atkinson et al. 2013; He et al. 2016).
Our studies are the first to show G9a and GLP are present in a complex under
basal and TNFα-stimulated conditions in the nucleus of adipocytes. We also observed
that a loss of both G9a and GLP in adipocytes does not have a significant effect on monoor di- methylation of H3K9 under basal conditions suggesting G9a and GLP may not be
the primary H3K9 methyltransferases in adipocytes. However, when G9a and GLP levels
are depleted in adipocytes and treated with TNFα, we observed a significant decrease in
mono- and di-methylation of H3K9. Knockdown approaches revealed that loss of both
G9a and GLP in adipocytes enhance TNFα’s ability to induce lipolysis and proinflammatory gene expression. Moreover, co-immunopreciptation experiments revealed
that p65, the major functional subunit of NF-kB that mediates the actions of TNFα, is only
present in a complex with G9a and GLP under TNFα-stimulated conditions in adipocytes.
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3.2. Materials and Methods
Cell culture
Murine 3T3-L1 preadipocytes (obtained from Dr. Howard Green at Harvard
University) were grown in Dulbecco’s Modified Eagle’s Media (DMEM) (Sigma-Aldrich,
St. Louis, MO) with 10% bovine calf serum. Two days after confluence, the preadipocytes
were induced to differentiate using a standard protocol and 3-isobutyl-methylxanthine,
dexamethasone, insulin (MDI) induction cocktail plus 10% fetal bovine serum (FBS) in
DMEM (Richard et al. 2017). HyClone calf and fetal bovine serum were purchased from
Thermo Scientific (Waltham, MA) or GE Healthcare Life Sciences (Marlborough, MA).
The medium was changed every 48-72 hours during growth and differentiation. Cells
were serum deprived by changing the medium to DMEM containing 1% calf serum for 16
– 24 h before treatment with murine TNFα. Recombinant murine TNFα was purchased
from Thermo Fisher (Waltham, MA; Cat #: PMC3013).
Small interfering RNA (siRNA)-mediated knockdown
3T3-L1 adipocytes (5-7 days post-MDI) were trypsinized and re-plated in 6-well or
12-well plates at a density of 5.8 x 105 cells/cm2 in antibiotic-free medium (10%
FBS/DMEM). Using the protocol from Dharmacon, adipocytes were transfected with 50
nM siRNA (Dharmacon, Lafayette, CO; Non-targeting siRNA Cat #: D-001810-10-50,
siRNA targeting G9a Cat #: L-053728-01-0005, siRNA targeting GLP Cat #: L-05904101-0005) and the DharmaFECT Duo reagent (Dharmacon, Lafayette, CO, Cat #: T-201003) in OptiMEM reduced serum medium (Thermo Fisher, Waltham, MA; Cat #:
31985088). Non-targeting siRNA was used as negative control. After 24hrs, siRNAcontaining media was removed, replaced with antibiotic-free 10% FBS/DMEM, and cells
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were transfected again with 50 nM siRNA. After 24 hours, the media was removed and
replaced with antibiotic-free 10% FBS/DMEM. Cell monolayers were collected 72 hours
following the initial transfection and harvested for protein in immunoprecipitation (IP)
buffer, and for RNA in buffer provided in the RNeasy mini kit (Qiagen, Hilden, Germany) to
assess knockdown efficiency. Knockdown of Cyclophilin B was used as a positive control
to assess siRNA transfection efficiency in 3T3-L1 adipocytes because it is a wellcharacterized housekeeping gene that is not affected by experimental treatments in
adipocytes and has been validated in our lab. (Dharmacon, Lafayette, CO; Cat #: D001820-02-05).
RNA analysis
Adipocyte monolayers were harvested in lysis buffer from the RNeasy mini kit and
total RNA was isolated from harvested cells using the RNeasy mini kit (Qiagen, Hilden,
Germany). 10 µl of purified RNA was used for reverse transcription (RT) PCR to generate
cDNA according to the Applied Biosystems protocol (Applied Biosystems, Foster City,
CA; Cat #: 4368813). cDNA was quantitated using the real-time quantitative PCR (qPCR)
method in a total volume of 10 µl (2 µl DNA and 8 µl reaction master mix) using an Applied
Biosystems 7900HT Fast Real-Time PCR System and the qPCR amplification program
specified in the kit (Clontech, Mountain View, CA; Cat #: RR420A). Cyclophilin B,
Ubiquitin B, and Nono were used as endogenous controls. The following mouse genes
were examined by RT-qPCR: Cyclophilin a, Cyclophilin b, Ubb, Nono, Ehmt2(G9a),
Ehmt1(GLP), Adiponectin, Lcn2, Il-6, Mcp1, Glut4, Atgl, Hsl, and Plin1 and using primers
purchased from Integrated DNA Technologies (IDT, Coralville, IA). Primer sequences for
each gene are shown in Table 1.
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Table 3.1. Primer sequences of each gene used in qPCR.

Whole cell extract preparation
Adipocyte monolayers were rinsed once with phosphate buffered saline (PBS) and
then harvested in either non-denaturing IP buffer or RIPA buffer as previously described
(Richard et al. 2017). The cell extract was subjected to a freeze/thaw cycle at -80°C and
then passed through a 20-gauge needle seven times. The whole cell extract was further
purified by centrifugation at 13,000 x g for 10 min at 4°C.
Subcellular fractionation
Mature 3T3-L1 adipocytes were treated with vehicle or murine TNFα prior to
subcellular fractionation. Adipocyte monolayers from twelve 10-cm culture plates were
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scraped into nuclear homogenization buffer (NHB) (20 mM Tris pH 7.4, 10 mM NaCl, and
3 mL MgCl2) as previously described (Richard et al. 2017). After adding 0.15% IGEPAL
CA-630 (from 10% stock) to the cell suspension, it was homogenized on ice using 16
strokes in a Dounce homogenizer. The extract was centrifuged at 2500 rpm in a Beckman
GS-6KR centrifuge with a swinging bucket rotor. Subsequently, the supernatant
containing cytosol and mitochondria was centrifuged as previously described (Richard et
al. 2017). The nuclear pellet from the first centrifugation was washed once with half of the
initial volume of NHB buffer and re-centrifuged at 4°C for 5 min at 500 rpm in the Beckman
GS-6KR centrifuge. The supernatant was discarded, while the nuclear pellet was
resuspended in IP buffer and incubated on ice for 1 hour. To break open the nuclei, the
nuclear extract was passed through a 20G needle four times and further purified by
centrifuging at 13,000 x g for 10 min at 4°C.
Measurement of protein concentration
Protein content of cell extracts was quantified using the Bicinchoninic acid (BCA)
assay kit (Sigma-Aldrich, St. Louis, MO; Cat #: BCA1).
Gel electrophoresis and immunoblotting
Samples were separated on 6%, 7.5%, 10%, or 15% sodium dodecyl sulfate (SDS)
polyacrylamide (PA) gels (acrylamide; National Diagnostics, Atlanta, GA; Cat #: EC-890)
and transferred to nitrocellulose membranes (BioRad, Hercules, CA; Cat #: 162-0115) in
25 mM Tris, 192 mM glycine, and 20% methanol. After the transfer, the membrane was
blocked in 5% milk for 1 hour at room temperature and then immunoblotted. Results were
visualized with horseradish peroxidase-conjugated secondary antibodies (Jackson
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ImmunoResearch, West Grove, PA) and enhanced chemiluminescence (Pierce/Thermo
Scientific, Waltham, MA).
Immunoprecipitation (IP)
Cell extracts (300µg total protein) were incubated with 5 µg of immunoprecipitating
antibody, diluted in IP buffer, overnight on a mini-tube rotator at 4°C. Protein A-conjugated
agarose beads (IPA300 Protein A Resin; Repligen, Waltham, MA; Cat #: 10-2003-02)
were added to the antibody-epitope mixture, and the conjugation reaction proceeded for
an additional 4 hours at 4°C with rotation. Following conjugation to the bead resin, the
beads were pelleted by centrifugation at 13,000 rpm for 3 min at 4°C. The supernatant
was removed by aspiration and the beads were washed 3 times with ice cold 1X IP buffer.
Between each wash, the beads were pelleted by centrifugation at 10,000 rpm for 3 min
at 4°C and the supernatant removed by aspiration. After the final wash, the IP antibody
and immunoprecipitated proteins were eluted from the bead resin into 2X SDS loading
buffer (LB) by boiling the samples for 10 min at 100°C. Samples were flicked every 2
minutes during heat step to ensure efficient elution. The samples were briefly centrifuged
and the supernatants analyzed by SDS-PAGE and immunoblotting. A mock sample
containing only IP antibody and IP buffer (no cell extract) was used as a negative control
for each IP experiment.
Measurement of glycerol and free fatty acid release
3T3-L1 adipocytes were transfected with either non-targeting or G9a and/or GLP
siRNA as described above. 54 hours later, media was changed to 1% calf/DMEM and
cells were treated with equivalent volume of vehicle (0.1% BSA/PBS) or 0.75 nM TNFα
overnight. After 16 hours, 1% calf/DMEM was removed and replaced with incubation
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media that consisted of 2% fatty acid free bovine serum albumin (BSA; Sigma-Aldrich, St.
Louis, MO; Cat #: A6003) and 0.1% glucose in glucose-free phenol red-free DMEM, and
the cells were treated again with vehicle (0.1% BSA/PBS) or 0.75 nM TNFα. After 2 hours,
500 μL of conditioned media was collected and stored at -20°C. Glycerol release was
measured using 25 μL of each sample according to the kit protocol (Millipore, Burlington,
MA; Cat #: OB100). Free fatty acid release was measured using 25 μL of each sample
according to the NEFA assay protocol (Wako Diagnostics, Mountain View, CA; HR Series
NEFA-HR(2) Color Reagent A 999-34691 HR Series NEFA-HR(2) Solvent A 995-34791
HR Series NEFA-HR(2) Color Reagent B 991-34891 HR Series NEFA-HR(2) Solvent B
993-35191).
Antibodies
Anti-G9a (PP-A8620A-00; mouse monoclonal) and anti-GLP (PP-B0422-00;
mouse monoclonal) antibodies were purchased from R&D Systems (Minneapolis, MN).
Anti-H3K9me1 (ab8896; rabbit polyclonal) and anti-STAT5A (ab32043; rabbit
monoclonal) antibodies were purchased from Abcam (Cambridge, UK). Anti-Adiponectin
(PA1-054; rabbit polyclonal) antibody was purchased from Thermo Scientific (Waltham,
MA). Anti-H3K9me2 (9753; rabbit polyclonal), anti-Histone H3 (14269; mouse
monoclonal), anti-HSL (4107; rabbit polyclonal), anti- Perilipin (3470; rabbit polyclonal),
and anti-β-actin (3700; mouse monoclonal) antibodies were purchased from Cell
Signaling (Danvers, MA).
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Statistical analysis
All data were analyzed by two-tailed unpaired Student’s t-test (using GraphPad
Prism 6). Results from studies of cultured adipocytes are shown as mean ± standard error
of the mean (SEM). Results were considered statistically significant when p < 0.05.
3.3. Results
There is evidence to show that G9a and GLP expression in adipocytes contributes
to metabolic health and loss of expression of either one of these methyltransferases is
associated with systemic metabolic dysfunction (Wang et al. 2012; Ohno et al. 2013).
Hence, we hypothesized that the loss of G9a or GLP might affect TNFα’s ability to
modulate gene expression and induce lipolysis in adipocytes. First, we performed siRNA
experiments to knockdown either G9a or GLP in fully differentiated 3T3-L1 adipocytes to
determine if G9a or GLP expression impacted TNFα-regulated gene expression. We used
qPCR to examine several TNFα-regulated genes and observed that loss of either G9a or
GLP did not have a significant effect on TNFα’s ability to regulate Lcn2, Il6, Mcp1,
Adiponectin, and Glut4 (data not shown).

In each siRNA-mediated knockdown

experiment, Western blot analysis was used to assess the level of G9a or GLP protein
knockdown and the effectiveness of TNFα treatment, as judged by decreased expression
of adiponectin. As shown in Figure 3.1, we effectively knocked down G9a protein
expression without significantly affecting the expression of GLP. In addition, we effectively
knocked down GLP protein expression without significantly affecting the protein
expression of G9a (Figure 3.2).
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Figure 3.1. Knockdown of G9a does not have a significant effect on mono-and dimethylation of H3K9 in 3T3-L1 adipocytes. Fully differentiated 3T3-L1 adipocytes were
transfected once per day for two days with non-targeting (NT) siRNA or G9a siRNA. After
54 hours, media was replaced with 10% FBS and cells were treated with 0.75 nM TNFα
overnight or equivalent volume of vehicle (0.1% BSA/PBS). After 16 hours, cells were retreated again with vehicle or TNFα for 2 hours. Finally, monolayers were harvested for
protein. 25 μg of total protein from whole cell extract samples were separated using SDSPAGE. Protein expression was visualized using Western blotting with the antibodies
indicated on the left panel. Histone H3 was used as a loading control for whole cell extract.
Three replicates were used for each treatment group in each individual experiment. This
is a representative figure of an experiment independently performed three times on
independent batches of adipocytes. Western blot results were quantified with Image
Studio Lite. The data are expressed as the mean ± SEM from three independent
experiments.
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G9a and GLP have been shown to be the primary methyltransferases for monoand di-methylation of H3K9 (Tachibana et al. 2002, 2005). Mono-methylation of H3K9 is
typically associated with transcriptional activation and di-methylation of H3K9 typically
associated with transcriptional repression (Barski et al. 2007). Interestingly, when we
examined these two histone marks by Western Blot analysis, we observed that siRNAmediated knockdown of G9a or GLP in mature adipocytes did not significantly decrease
mono- or di- methylation of H3K9 under basal (vehicle) conditions or TNFα-stimulated
conditions (Figure 3.1 and Figure 3.2). However, TNFα did reduce the expression of
adiponectin. We also assessed whether G9a or GLP expression had an impact on TNFαinduced lipolysis. Glycerol release was measured from mature adipocytes following an
overnight (eighteen hour) TNFα treatment in control, G9a-knockdown, or GLPknockdown adipocytes. The data showed the expected induction of lipolysis following
overnight TNFα treatment. However, there were no differences in glycerol release in
adipocytes with reduced G9a or GLP expression compared to control adipocytes (Figure
3.3).
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Figure 3.2. Knockdown of GLP does not have a significant effect on mono-and dimethylation of H3K9 in 3T3-L1 adipocytes. Fully differentiated 3T3-L1 adipocytes were
transfected once per day for two days with non-targeting (NT) siRNA or GLP siRNA. After
54 hours, media was replaced with 10% FBS and cells were treated with 0.75 nM TNFα
overnight or equivalent volume of vehicle (0.1% BSA/PBS). After 16 hours, cells were retreated again with vehicle or TNFα for 2 hours. Finally, monolayers were harvested for
protein. 25 μg of total protein from whole cell extract samples were separated using SDSPAGE. Protein expression was visualized using Western blotting with the antibodies
indicated on the left panel. Histone H3 was used as a loading control for whole cell extract.
Three replicates were used for each treatment group in each individual experiment. This
is a representative figure of an experiment independently performed three times on
different groups of adipocytes. Western blot results were quantified with Image Studio
Lite. The data are expressed as the mean ± SEM from three independent experiments .
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Figure 3.3. Knockdown of either G9a or GLP does not have a significant effect on basal
or TNFα-induced glycerol release in 3T3-L1 adipocytes. Fully differentiated 3T3-L1
adipocytes were transfected once per day for two days with non-targeting (NT) siRNA or
either G9a or GLP siRNA. After 54 hours, media was replaced with incubation media and
cells were treated with 0.75 nM TNFα or equivalent volume of vehicle (0.1% BSA/PBS)
overnight. After 16 hours, cells were treated again with vehicle or TNFα for 2 hours. 25
μL of conditioned medium was used for free fatty acid assay and glycerol assay.
Statistical significance was determined using an unpaired Student’s t-test. This is a
representative figure of an experiment independently performed three times on different
groups of adipocytes.
Previous studies have demonstrated that G9a and GLP have to be in a complex
in order to exert their catalytic activity (Tachibana et al. 2005), but there is data to indicate
that the formation and activity of this complex is tissue specific and dependent on
developmental stage (Wang et al. 2012; Ohno et al. 2013; Antignano et al. 2014; Liu et
al. 2015). To our knowledge, it is not known if G9a and GLP physically interact in
adipocytes. We performed co-immunoprecipitation with a G9a antibody followed by
Western blotting using an anti-GLP antibody in the absence or presence of an acute thirty
minute TNFα treatment of fully differentiated 3T3-L1 adipocytes. We examined fresh
whole cell extract (WCE) and WCE that was subjected to one freeze thaw since freeze
thaw cycles can aid in cell lysis, but could potentially disrupt protein-protein interactions.
As shown in Figure 3.4, our results revealed that G9a interacts with GLP under basal
(vehicle) and TNFα-stimulated conditions. Signal transducer and activator of transcription
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5A (STAT5A) was used as a negative control to show the specificity of the interaction
between G9a and GLP.

Figure 3.4. G9a and GLP physically interact under basal and TNFα-stimulated conditions
in 3T3-L1 adipocytes. (A) Fully differentiated 3T3-L1 adipocytes were treated with 0.75
nM TNFα or an equivalent volume of vehicle (0.1% BSA/PBS) for 30 minutes. Monolayers
were collected. As shown in the left-hand portion of the figure, 200 μg total protein in
whole cell extract samples were immunoprecipitated (IP) with an anti-G9a antibody. The
mock sample was used as a negative control and contained anti-G9a antibody without
cell extract. The right-hand portion of the figure are direct western blot controls containing
25 μg total protein that were directly subjected to Western blotting without IP. This is a
representative figure of an experiment independently performed three times.

Since we observed knockdown of either G9a or GLP did not have a significant
effect on TNFα-mediated gene expression or lipolysis, we used siRNA to simultaneously
knockdown both G9a and GLP protein expression in fully differentiated 3T3-L1
adipocytes. To determine if G9a and GLP expression had any effect on TNFα to modulate
gene expression, we examined the same genes as previously described. As shown in
Figure 3.5, we effectively knocked down G9a and Glp mRNA expression. Interestingly,
qPCR analysis revealed knocking down both G9a and GLP in fully differentiated
adipocytes increased Adiponectin and Glut4 mRNA expression under basal conditions
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(Figure 3.5). In knockdown adipocytes, these genes were less decreased by TNFα
treatment (Figure 3.5). Additionally, we observed that loss of G9a and GLP levels in
adipocytes enhanced TNFα’s ability to induce gene expression of Lcn2, Il6, and Mcp1
(Figure 3.6). Notably, the loss of expression of these methyltransferases did not affect the
expression of these genes under basal conditions.

Figure 3.5. Simultaneous knockdown of G9a and GLP increases Adiponectin and Glut4
gene expression in 3T3-L1 adipocytes. Fully differentiated 3T3-L1 adipocytes were
transfected once per day for two days with non-targeting (NT) siRNA or G9a/GLP siRNA.
After 54 hours, media was replaced with incubation media and cells were treated with
0.75 nM TNFα or equivalent volume of vehicle (0.1% BSA/PBS) overnight. After 16 hours,
cells were treated again with vehicle or TNFα for 2 hours. Finally, monolayers were
harvested for RNA. Total RNA was isolated and subjected to quantitative RT-PCR
analysis. The examined genes (each represented by separate graph) were normalized to
Cyclophilin A. Three replicates were used for each treatment group in each individual
experiment. This is a representative figure of an experiment independently performed
three times on different groups of adipocytes. The data are expressed as the mean ±
SEM from three independent experiments. Statistical significance was determined using
an unpaired Student’s t-test and assigned as * p<0.05, ** p<0.01, and **** p<0.0001.
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Figure 3.6. Simultaneous knockdown of G9a and GLP significantly enhances TNFα’s
ability to induce pro-inflammatory gene expression in 3T3-L1 adipocytes. Fully
differentiated 3T3-L1 adipocytes were transfected once per day for two days with nontargeting (NT) siRNA or G9a/GLP siRNA. After 54 hours, media was replaced with
incubation media and cells were treated with 0.75 nM TNFα or equivalent volume of
vehicle (0.1% BSA/PBS) overnight. After 16 hours, cells were treated again with vehicle
or TNFα for 2 hours. Finally, monolayers were harvested for RNA. Total RNA was isolated
and subjected to quantitative RT-PCR analysis. The examined genes (each represented
by separate graph) were normalized to Cyclophilin A. Three biological replicates were
used for each treatment group in each individual experiment. This is a representative
figure of an experiment independently performed three times on different groups of
adipocytes. The data are expressed as the mean ± SEM from three independent
experiments. Statistical significance was determined using an unpaired Student’s t-test
and assigned as ** p<0.01 and *** p<0.001.
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Western blot analysis was used to assess the level of G9a and GLP protein
knockdown and the effectiveness of TNFα treatment, as judged by reduced adiponectin
protein levels (Figure 3.7). As observed with single knockdowns (Figure 3.1 and 3.2),
siRNA-mediated knockdown of both G9a and GLP protein levels did not have a significant
effect on mono- and di- methylation of H3K9 under basal conditions. However, when
adipocytes were depleted of G9a and GLP then treated with TNFα overnight, we
observed a decrease in mono- and di-methylation of H3K9 expression (Figure 3.7).
Additionally, we also observed a modest increase in adiponectin protein expression in
G9a/GLP-knockdown adipocytes under basal conditions. The levels of histone H3 were
examined to demonstrate even loading of protein samples and that the observed changes
in histone H3 methylation are not due to alterations in protein levels.
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Figure 3.7. Simultaneous knockdown of G9a and GLP decreases mono- and dimethylation of H3K9 expression under TNFα-stimulated conditions in 3T3-L1 adipocytes.
Fully differentiated 3T3-L1 adipocytes were transfected once per day for two days with
non-targeting (NT) siRNA or G9a siRNA. After 54 hours, media was replaced with 10%
FBS and cells were treated with 0.75 nM TNFα overnight or equivalent volume of vehicle
(0.1% BSA/PBS). After 16 hours, cells were re-treated again with vehicle or TNFα for 2
hours. Finally, monolayers were harvested for protein. 25 μg of total protein from whole
cell extract samples were separated using SDS-PAGE. Protein expression was visualized
using Western blotting with the antibodies indicated on the left panel. Histone H3 was
used as a loading control for whole cell extract. Three biological replicates were used for
each treatment group in each individual experiment. This is a representative figure of an
experiment independently performed three times on different groups of adipocytes.
Western blot results were quantified with Image Studio Lite. The data are expressed as
the mean ± SEM from three independent experiments. Statistical significance was
determined using a Student’s t-test and assigned as * p<0.05.
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.
Since we observed that loss of G9a and GLP levels had an effect on TNFα’s ability
to induce pro-inflammatory gene expression (Figure 3.6), we also assessed whether G9a
and GLP expression also impacts TNFα-induced lipolysis in murine 3T3-L1 adipocytes.
Lipolysis is a highly-regulated metabolic process that involves the breakdown of
triglycerides into fatty acids and glycerol, which are subsequently released into circulation.
As shown in Figure 3.8, TNFα-induced lipolysis was assessed by measurement of both
glycerol and free fatty acid release into the culture medium. Interestingly, siRNA-mediated
double knockdown of G9a and GLP significantly enhanced the effect of TNFα on lipolysis,
but did not impact basal lipolysis (Figure 3.8). Although TNFα increases lipolysis, it has
also been shown to reduce gene expression of proteins that promote lipolysis, such as
adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL), and perilipin 1
(PLIN1) (Rydén et al. 2004; Kralisch et al. 2005a). We used qPCR analysis to examine
mRNA expression of these genes in control adipocytes and adipocytes with depleted
levels of both G9a and GLP. As shown in Figure 3.9A, knocking down both G9a and GLP
in fully differentiated adipocytes increases Atgl, Hsl, and Plin1 mRNA expression
compared to control adipocytes, and this effect occurred independent of TNFα treatment.
However, Western blot analysis revealed that TNFα reduced ATGL, HSL, and PLIN1
levels, but there were no significant changes between G9a/GLP-knockdown adipocytes
and control adipocytes (Figure 3.9B). β-actin expression was measured to demonstrate
even loading of protein samples.
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Figure 3.8. Simultaneous knockdown of G9a and GLP increases TNFα’s ability to induce
lipolysis in 3T3-L1 adipocytes. Fully differentiated 3T3-L1 adipocytes were transfected
once per day for two days with non-targeting (NT) siRNA or G9a/GLP siRNA. After 54
hours, media was replaced with incubation media and cells were treated with 0.75 nM
TNFα or equivalent volume of vehicle (0.1% BSA/PBS) overnight. After 16 hours, cells
were treated again with vehicle or TNFα for 2 hours. 25 μL of conditioned medium was
used for free fatty acid assay and glycerol assay. This is a representative figure of an
experiment independently performed two times on different groups of adipocytes. The
data are expressed as the mean ± SEM from three independent experiments. Statistical
significance was determined using a Student’s t-test and assigned as * p<0.05 and ***
p<0.001.
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A.

Figure 3.9. Simultaneous knockdown of G9a and GLP increases lipolytic gene expression
but does not have an effect on lipolytic protein expression. Fully differentiated 3T3-L1
adipocytes were transfected once per day for two days with non-targeting (NT) siRNA or
G9a siRNA. After 54 hours, media was replaced with 10% FBS and cells were treated
with 0.75 nM TNFα overnight or equivalent volume of vehicle (0.1% BSA/PBS). After 16
hours, cells were re-treated again with vehicle or TNFα for 2 hours. Finally, monolayers
were harvested for RNA and protein. (A) Total RNA was isolated and subjected to
quantitative RT-PCR analysis. The examined genes (each represented by separate
graph) were normalized to Cyclophilin A. Statistical significance was determined using a
Student’s t-test and assigned as ** p<0.01, *** p<0.001, and **** p<0.0001. (B) 25 μg of
total protein was separated using SDS-PAGE. Protein expression was visualized using
Western blotting and the antibodies indicated on the left of panel. Three biological
replicates were used for each treatment group in each individual experiment. This is a
representative figure of an experiment independently performed three times on different
groups of adipocytes.

RelA (also known as p65) is the major functional subunit of the transcription factor
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). p65 mediates
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some actions of TNFα and has a prominent role in inflammation. Since Lcn2, Il6, and
Mcp1 are p65 target genes induced by TNFα (Libermann & Baltimore 1990; Ping et al.
1999; Zhao et al. 2014), we hypothesized that G9a and GLP could potentially be present
in a protein complex with p65. To test this hypothesis, we performed coimmunoprecipitation with a G9a antibody followed by Western blotting using an anti-p65
antibody and we examined both cytosolic and nuclear extracts from mature 3T3-L1
adipocytes in the absence or presence of an acute thirty minute TNFα treatment. This
TNFα treatment is known to induce p65 translocation to the nucleus as confirmed in direct
western portion of Figure 3.10. A mock sample containing anti-G9a antibody without cell
extract was used as a negative control. These novel observations revealed that p65
interacts with G9a and GLP in the nucleus of adipocytes under endogenous conditions
and the formation of this complex is dependent on TNFα treatment (Figure 3.10). Again,
we used STAT5A expression as a negative control to show the specificity of the
interaction between G9a and GLP. As shown in the direct western portion, the majority of
STAT5A is present in the cytosol and not regulated by TNFα. This is consistent with
published data that TNFα does not activate and induce translocation of STAT5A to the
nucleus in 3T3-L1 adipocytes (Floyd et al. 2007).
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Figure 3.10. p65 is present in a complex with G9a and GLP under TNFα-stimulated
conditions in 3T3-L1 adipocytes. (A) Fully differentiated 3T3-L1 adipocytes were treated
with 0.75 nM TNFα or an equivalent volume of vehicle (0.1% BSA/PBS) for 30 minutes.
Monolayers were collected. As shown in the left-hand portion of the figure, cytosolic and
nuclear protein extracts (300 μg total protein/sample) were immunoprecipitated (IP) with
an anti-G9a antibody. The mock sample was used as a negative control and contained
anti-G9a antibody without cell extract. The right-hand portion of the figure are direct
western blot controls containing 25 μg total protein that were directly subjected to Western
blotting without IP. This is a figure of an experiment independently performed one time.
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3.4. Discussion
It is well-established that G9a and GLP are the primary methyltransferases for
mono-and di-methylation of H3K9 in several cell types. Previous studies used Western
blot to examine histone methylation at various sites in primary murine brown
preadipocytes and G9a-knockout brown preadipocytes. They observed that deletion of
G9a results in a robust reduction of di-methylation of H3K9 suggesting that G9a is the
primary methyltransferase of di-methylation of H3K9 in primary murine brown
preadipocytes (Wang et al. 2012). To our knowledge, we were the first to assess if monoand di-methylation of H3K9 is affected by G9a and/or GLP expression in fully
differentiated 3T3-L1 “white” adipocytes under basal and TNFα-stimulated conditions. We
first performed individual siRNA-mediated knockdowns of G9a or GLP to examine monoand di-methylation of H3K9. Initially, our observations that these two histone sites were
unaffected in either G9a-knockdown or GLP-knockdown adipocytes compared to control
adipocytes was surprising (Figure 3.1 and 3.2). These studies suggested that G9a or GLP
alone are not the primary regulators of H3K9 methylation. However, there is evidence
that mono- and di- methylation of H3K9 can be modulated by other methyltransferases
including SETDB1 and SUV39H1 (Rea et al. 2000; Peters et al. 2003; Wang et al. 2003).
It is highly plausible that knocking down either G9a or GLP results in compensation by
another H3K9 methyltransferase. Studies have also shown that G9a, GLP, SUV39H1,
and SETDB1 can form a multimeric complex and cooperate to establish H3K9
methylation in euchromatin and heterochromatin (Fritsch et al. 2010).
Considering H3K9 can be regulated by other methyltransferases prompted us to
knock down both G9a and GLP concurrently. It was surprising that mono- and di-
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methylation of H3K9 was only affected by loss of both G9a and GLP when adipocytes
were treated with TNFα to induce metabolic dysfunction, but not under basal conditions
(Figure 3.7). This could suggest that the increase we observe in Adiponectin and Glut4
gene expression is not dependent on G9a and GLP’s H3K9 methyltransferase activity
and most likely results from methylation of a non-histone substrate. Furthermore, the
observed reduction in di-methylation of H3K9, a histone mark that is enriched in the
transcriptional start sites of silenced genes, could contribute to the increases in proinflammatory gene expression in TNFα–stimulated adipocytes with depleted G9a/GLP.
In addition to this observation, our co-immunoprecipitation experiments revealed that
endogenous G9a and GLP proteins physically interact under basal conditions (Figure
3.4). Although it is not statistically significant, we consistently observed a trend that the
G9a and GLP interaction is modestly enhanced under acute TNFα-stimulated conditions
compared to basal conditions (Figure 3.4). Considering initial studies showed G9a and
GLP had to be present in a complex in order to exert their methyltransferase activity, the
enhanced interaction between G9a and GLP in response to TNFα could suggest that the
catalytic activity of G9a and GLP is only induced under TNFα-stimulated conditions.
However, our results are correlative and additional experiments are needed to assess if
the G9a/GLP complex directly binds to the promoters of Lcn2, Il6, and Mcp1 genes. It will
also be important to determine if loss of G9a and GLP expression reduces di-methylation
of H3K9 at those specific gene promoter regions in response to TNFα.
NF-κB is a transcription factor that can be activated by TNFα as well as other proinflammatory cytokines. Since there was evidence suggesting that G9a and GLP have a
role in inflammation in immune cells and cancer cells through interactions with members
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of NF-κB family (p65 and p50) (Ea et al. 2012; Liu et al. 2014), we examined the actions
of TNFα on adipocytes with reduced levels of G9a and GLP. TNFα stimulates p65
translocation to the nucleus where it directly binds to NF-κB sites in the promoters of proinflammatory genes such as Lcn2, Il6, and Mcp1 (Libermann & Baltimore 1990; Zhao et
al. 2014). Although controversial, increased circulating LCN2 is associated with insulin
resistance and increased inflammation (Yan et al. 2007; Zhang et al. 2008). We examined
if G9a and GLP expression had an effect on TNFα’s ability to induce pro-inflammatory
gene expression in adipocytes. Surprisingly, we observed that TNFα stimulation of Lcn2,
Il6, and Mcp1 gene expression was significantly increased in G9a/GLP-deficient
adipocytes compared to control adipocytes (Figure 3.5), which suggests that G9a and
GLP expression may have a role in suppressing TNFα’s ability to induce genes
associated with inflammation. This effect could be considered metabolically unfavorable.
There is emerging evidence that the p65 subunit of NF-κB can be regulated through
methylation on various lysine residues. Studies suggest lysine methyltransferases are
recruited to specific promoter regions after NF-κB translocates to the nucleus and binds
to its target genes. Once methyltransferases are recruited to DNA, they can methylate
lysine residues on nearby histones as well as NF-κB (Lu & Stark 2015). Since we
observed that p65 only associates with G9a and GLP under TNFα-stimulated conditions
(Figure 3.10), we hypothesize the G9a/GLP complex regulates the transcriptional activity
of p65 through methylation in response to TNFα in adipocytes.
Chronic TNFα treatment induces insulin resistance in 3T3-L1 adipocytes that is
accompanied by significant reductions in expression of proteins involved in insulin
signaling; insulin receptor (IR), insulin receptor substrate-1 (IRS-1), and the insulin-
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regulated glucose transporter GLUT4 (Stephens et al. 1997). In addition, TNFα can
repress adiponectin gene expression in mouse and human adipocytes (Fasshauer et al.
2002, Degawa-Yamauchi et al. 2005). We consistently observed that simultaneous loss
of G9a and GLP protein resulted in increased Adiponectin and Glut4 gene expression,
particularly under basal (vehicle conditions) (Figure 3.6). Both increased GLUT4 protein
expression in adipocytes (Carvalho et al. 2005, Atkinson et al. 2013) and increased
adiponectin levels (Fu et al. 2005) are associated with improvements in insulin sensitivity.
Although previous studies have suggested a role of G9a in hepatic insulin signaling (Xue
et al. 2018), it is not known if G9a and/or GLP impact insulin signaling in white adipocytes.
Additional experiments are needed to determine if the loss of G9a/GLP expression in
adipocytes is metabolically favorable by assessing if G9a and GLP expression affects
insulin signaling and glucose uptake in adipocytes.
TNFα is a potent inducer of lipolysis and has been shown to increase basal
lipolysis in adipocytes isolated from human subcutaneous adipose tissue (SAT) (Rydén
et al. 2004). However, the underlying mechanism of TNFα-induced lipolysis remains
unknown. It typically takes greater than six hours to detect TNFα-induced changes in
lipolysis in 3T3-L1 adipocytes, which suggests that this regulation is largely mediated by
genomic effects. Experiments performed in human adipocytes demonstrated that the NFκB signaling pathway is important for the lipolytic response to TNFα (Laurencikiene et al.
2007). As shown in Figure 3.8, loss of G9a and GLP increases TNFα-induced lipolysis
suggesting that the loss of G9a and GLP in adipocytes may contribute to the metabolically
unhealthy phenotype of the G9a and GLP adipocyte-specific knockout mice. Enhanced
lipolysis increases circulating levels of glycerol/free fatty acids; a clinical manifestation
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considered harmful and typically associated with metabolically unhealthy obesity and
insulin resistance (Arner & Rydén 2015). Additionally, elevated free fatty acids in
circulation can lead to ectopic storage in skeletal muscle and liver (Frayn et al. 2006). Our
results show an increase in glycerol and free fatty acid release from TNFα-stimulated
G9a/GLP-deficient adipocytes that occurs in a cell-autonomous manner and suggest that
G9a and GLP play a role in restricting TNFα’s ability to induce lipolysis. Since TNFα
affects the expression of proteins known to regulate lipolysis (Yang et al. 2011), we
examined if G9a/GLP expression had an effect on gene or protein expression of ATGL,
HSL, and PLIN. As previously documented, TNFα robustly reduced mRNA expression of
Atgl, Hsl, and Plin1 (Rydén et al. 2004; Kralisch et al. 2005b). Interestingly, adipocytes
with reduced levels of G9a and GLP had increased Atgl, Hsl, and Plin1 mRNA expression
independent of TNFα treatment (Figure 3.9). However, this effect did not translate to
similar changes in protein expression suggesting that TNFα-induced lipolysis is not due
to increased expression of these three fundamental prolipolytic proteins. Further studies
are needed to determine the mechanism of G9a and GLP’s ability to regulate TNFαinduced lipolysis.
Overall, our novel data showing that loss of both G9a/GLP enhances TNFα’s ability
to induce pro-inflammatory gene expression and lipolysis are consistent with the
metabolically unfavorable phenotype observed in G9a and GLP adipocyte-specific KO
mice (Wang et al. 2012; Ohno et al. 2013). Our observations suggest that G9a and GLP
have a role in fine-tuning the transcriptional activity of p65 in response to TNFα
stimulation. Although we demonstrate that G9a and GLP expression affects the ability of
TNFα to regulate gene expression and lipolysis, further studies are needed to determine
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if the observed effects are dependent on G9a and GLP’s H3K9 methylation and/or nonhistone substrate methylation. We are also interested in investigating if these responses
are specific to TNFα or if these pathways are similarly regulated by other pro-inflammatory
cytokines when the expression of these methyltransferases are reduced. Ultimately,
these studies underscore the complexity of epigenetic modifiers. Under basal conditions,
loss of G9a and GLP result in a metabolically beneficial phenotype as judged by increased
Adiponectin and Glut4 gene expression (Figure 3.5). Yet, in the presence of metabolic
dysfunction, loss of these proteins facilitates this effect by increasing TNFα-induced proinflammatory gene expression and lipolysis (Figure 3.6 and 3.8). Nevertheless, these
novel observations warrant further research. Additional studies are needed to identify if
other lysine methyltransferases are present in the G9a/GLP complex, to assess if
G9a/GLP expression affects the expression of other TNFα-regulated genes in adipocytes,
and to examine if our observations are reproducible in other cellular models such as
primary murine adipocytes and human adipocytes.
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CHAPTER 4. CONCLUDING REMARKS
4.1. Research Summary and Significance
Obesity has become a global epidemic and characterized by excess energy
storage in AT. Obesity is a risk factor for Type 2 diabetes (T2D), cardiovascular disease,
hypertension, mental disorders, and some cancers. The immune cells in AT produce and
secrete pro-inflammatory cytokines which have a profound impact on adipocyte function.
TNFα is a pro-inflammatory cytokine that is produced in AT macrophages and acts on
adipocytes in a paracrine manner to induce insulin resistance. Genetic mouse models
have demonstrated that DBC1, G9a, and GLP expression have a role in modulating
adiposity and metabolic health. Although DBC1 global knockout mice had increased
adiposity, they maintained insulin sensitivity, had lower circulating free fatty acids, and
were protected against atherosclerosis and liver steatosis following diet- induced obesity
(Escande et al. 2015). Previous studies suggested that DBC1 may have a proinflammatory role in adipocytes (Moreno-Navarrete et al. 2015b). Conversely, adipocytespecific deletion of G9a or GLP expression results in increased adiposity as well but is
also associated with increased insulin levels in circulation and ectopic lipid deposition in
the liver (Wang et al. 2012; Ohno et al. 2013). Moreover, these studies have
demonstrated the role of G9a in adipocyte development and the importance of GLP in
brown adipose tissue (BAT) thermogenesis and glucose homeostasis. However, the
function and underlying molecular mechanisms of DBC1, G9a, and GLP in white adipose
tissue (WAT) in conditions of obesity and Type 2 diabetes are largely unknown.
Considering WAT is a major contributor to metabolic health, we became interested in
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investigating how DBC1, G9a, and GLP impact adipocyte function and modulate gene
expression in white adipocytes.
We investigated if loss of any of DBC1, G9a, or GLP could disrupt TNFα’s
regulation of metabolically unhealthy gene expression or ability to induce lipolysis in
adipocytes. Our studies revealed siRNA-mediated loss of DBC1 expression had no effect
on TNF’s ability to regulate gene expression in adipocytes. However, we consistently
observed that loss of DBC1 increased Glut4 mRNA expression. Interestingly, we
demonstrated that depleting DBC1 expression in adipocytes reduces TNFα’s ability to
induce glycerol and free fatty acid release and suggests that DBC1 has a role in the ability
of TNFα to induce lipolysis. Together, these observations show loss of DBC1 promotes
metabolic health. In contrast, when we used TNFα to induce metabolic dysfunction, our
studies revealed that siRNA-mediated simultaneous knockdown of G9a and GLP
exacerbates TNFα’s ability to induce pro-inflammatory gene expression. Additionally, we
show that simultaneous loss of G9a and GLP in adipocytes enhances TNFα’s ability to
induce lipolysis. Both of these novel observations could be associated with a
metabolically unhealthy phenotype in adipocytes. Although our studies showed the
expected reduction in Adiponectin and Glut4 mRNA expression in response to TNFα, the
increase we observed in these genes in adipocytes with decreased G9a and GLP
expression is not dependent on TNFα stimulation. Moreover, increased Adiponectin and
Glut4 gene expression could be considered metabolically beneficial and associated with
enhanced insulin sensitivity. Collectively, our in vitro studies performed in murine
adipocytes have identified DBC1, G9a and GLP as novel proteins that increase Glut4
gene expression and have a direct or indirect role TNFα-induced lipolysis.
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The NF-κB signaling pathway is utilized by several pro-inflammatory cytokines
including TNFα and studies suggest NF-κB has a role in lipolysis. In order to investigate
if G9a and GLP interact with NF-κB, we performed co-immunoprecipitation experiments
which revealed that p65, the major functional subunit of NF-κB, is present in a complex
with G9a and GLP exclusively in TNFα-induced conditions. Considering loss of G9a/GLP
increases TNFα’s ability to induce pro-inflammatory gene expression and p65 is present
in a complex with G9a/GLP under TNFα treated conditions suggests that G9a and GLP
could have a potential role in regulating the transcriptional activity of NF-kB and its ability
to induce inflammation in adipocytes.
4.2. Future Directions
Studies over the past three decades have established AT as an intricate multifunction organ that communicates with other tissues and contributes to whole-body
metabolic health. In humans, white adipose tissue (WAT) consists of metabolically
protective subcutaneous depots and visceral depots that are linked to insulin resistance
(Chusyd et al. 2016). AT has plasticity, is innervated, and has endocrine functions that
contribute to insulin sensitivity, lipid and glucose homeostasis, and inflammation (Rosen
& Spiegelman 2006, 2014; Athyros et al. 2010). However, some obese individuals are
metabolically healthy and exhibit characteristics such as insulin sensitivity, healthy AT
expansion, metabolic flexibility, increased circulating adiponectin, and decreased
systemic inflammation (Samocha-Bonet et al. 2014). Studies over the past few decades
have aimed to determine underlying mechanisms that contribute to decreased basal
lipolysis and unrestrained expansion of subcutaneous fat depots in metabolically healthy
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obese. However, potential epigenetic modifications that contribute to the metabolically
healthy phenotype have not been widely investigated.
Although our novel observations show that loss of G9a and GLP has effects on
TNFα-regulated

gene

expression

and

TNFα-induced

lipolysis,

the

underlying

mechanisms for these effects remain to be elucidated. Previous studies have reported
that the physical association of G9a and GLP occurs between their SET domains and is
important for their methyltransferase activity. Moreover, single amino acid substitutions
within the SET domain and ankyrin repeats of G9a and GLP suggested the SET domain
of G9a is more important for lysine methyltransferase activity and the ankyrin repeats of
GLP is more important for protein-protein interactions. To further investigate the
p65/G9a/GLP interaction, we can generate mutant forms of G9a and GLP by substituting
single amino acids within the ankyrin repeats of G9a and GLP and using coimmunoprecipitation to observe if ankyrin repeat mutations perturb the interaction with
p65. These experiments would also determine if G9a and/or GLP directly associates with
p65.
One major limitation to our studies is that we have only performed experiments in
vitro in murine 3T3-L1 adipocytes. The 3T3-L1 cell line is widely used in adipocyte biology
as these cells readily differentiates into mature adipocytes. In addition, these cells exhibit
gene expression profiles similar to white adipocytes and have endocrine capabilities of
fat cells in vivo. Hence, the 3T3-L1 cells are widely used in mechanistic studies and to
assess cell autonomous adipocyte functions. However, it will be critical to take our most
profound observations and assess if the results are reproducible in other cellular models
such as primary murine adipocytes and human adipocytes. We could also determine if
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there are depot specific differences using primary murine adipocytes isolated from
inguinal and mesenteric WAT. The inguinal fat pad is most analogous to human
subcutaneous white adipose tissue and the mesenteric fat pad is most similar to human
visceral white adipose tissue (Chusyd et al. 2016) . It is also important to examine if our
results are reproducible in human adipocytes. Zenbio has commercially available
characterized subcutaneous and omental human adipocytes. If these results are
reproducible in these cellular models, RNA-sequencing can be employed to investigate
expressed genes and pathways that are altered in TNFα treated adipocytes with reduced
levels of either DBC1, G9a, or GLP. RNA-sequencing may also assist in determining the
genes responsible for the observed effects on TNFα-induced lipolysis. These studies will
provide additional insight to the role of DBC1, G9a, and GLP in TNFα-regulated gene
expression and TNFα action in adipocytes.
The cellular models proposed above will be critical to gain insight into function of
DBC1, G9a, and GLP on TNFα mediated actions in white adipocytes. However, it is
important to determine the in vivo regulation and function of DBC1, G9a, and GLP
expression in white adipose tissue of a mammalian model in response to diet-induced
obesity (DIO). DIO in mice is a highly relevant model to study obesity and Type 2 diabetes
(T2D). Most studies have shown that it takes 18 weeks for C57BL/6J mice fed a high fat
diet to become obese, insulin resistant, and have increased TNFα in AT (Lumeng et al.
2007). To better understand the function of these nuclear proteins in adipocytes in the
context of obesity and Type 2 diabetes under physiological conditions, it will be critical to
generate a doxycycline-inducible adipocyte-specific knockout mouse model for each of
these genes using the adiponectin promoter to confer adipocyte specific gene
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manipulation. This would be a more suitable mouse model to gain insight on the function
of DBC1, G9a, and GLP in adipocytes because adiponectin is exclusively expressed in
adipocytes whereas aP2 (also known as FABP4, fatty acid binding protein 4) is also
expressed in macrophages. Moreover, generation of a doxycycline-inducible knockout
would allow us the ability to investigate the function of DBC1, G9a, and GLP in mature
adipocytes independent of potential regulation that could occur during development.
Doxycycline-inducible mouse models would also be beneficial in assessing acute and
chronic compensation that can occur through partially redundant pathways. We could
also assess DBC1, G9a, and GLP mRNA and protein levels in every WAT depot of female
and male mice fed high fat diet (HFD) versus a low fat diet (LFD) to determine if there are
depot-specific and/or sex-specific differences in DBC1, G9a, and GLP expression.
Examining DBC1, G9a, and GLP’s expression in WAT is highly valuable to study given
the known differences in fat depot function. Examining DBC1, G9a, and GLP’s expression
in WAT is highly valuable to study given the known differences in fat depot function.

Although our studies provide novel insight into how DBC1, G9a, and GLP impact
adipocyte function and modulates gene expression in white adipocytes under TNFαinduced metabolic dysfunction, future studies should focus on the role of these nuclear
proteins in WAT in conditions of obesity and T2D.

81

REFERENCES
Able AA, Richard AJ & Stephens J 2018 Loss of DBC1 (CCAR2) affects TNFα-induced
lipolysis and Glut4 gene expression in murine adipocytes. Journal of Molecular
Endocrinology 61 195–205. (doi:10.1530/JME-18-0154)
Antignano F, Burrows K, Hughes MR, Han JM, Kron KJ, Penrod NM, Oudhoff MJ, Wang
SKH, Min PH, Gold MJ et al. 2014 Methyltransferase G9A regulates T cell
differentiation during murine intestinal inflammation. The Journal of Clinical
Investigation 124 1945. (doi:10.1172/JCI69592)
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I,
Nakamura T, Miyaoka K et al. 1999 Paradoxical Decrease of an Adipose-Specific
Protein, Adiponectin, in Obesity. Biochemical and Biophysical Research
Communications 257 79–83. (doi:10.1006/bbrc.1999.0255)
Arner P & Kulyté A 2015 MicroRNA regulatory networks in human adipose tissue and
obesity. Nature Reviews Endocrinology 11 276–288. (doi:10.1038/nrendo.2015.25)
Arner P & Rydén M 2015 Fatty Acids, Obesity and Insulin Resistance. Obesity Facts 8
147–155. (doi:10.1159/000381224)
Arner E, Mejhert N, Kulyte A, Balwierz PJ, Pachkov M, Cormont M, Lorente-Cebrian S,
Ehrlund A, Laurencikiene J, Heden P et al. 2012 Adipose Tissue MicroRNAs as
Regulators of CCL2 Production in Human Obesity. Diabetes 61 1986–1993.
(doi:10.2337/db11-1508)
Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P & Mikhailidis DP 2010 Should
adipokines be considered in the choice of the treatment of obesity-related health
problems? Current Drug Targets 11 122–135.
Atkinson BJ, Griesel BA, King CD, Josey MA & Olson AL 2013 Moderate GLUT4
overexpression improves insulin sensitivity and fasting triglyceridemia in high-fat
diet-fed transgenic mice. Diabetes 62 2249–2258. (doi:10.2337/db12-1146)
Bao L, Chen Y, Lai H-T, Wu S-Y, Wang JE, Hatanpaa KJ, Raisanen JM, Fontenot M,
Lega B, Chiang C-M et al. 2018 Methylation of hypoxia-inducible factor (HIF)-1α by
G9a/GLP inhibits HIF-1 transcriptional activity and cell migration. Nucleic Acids
Research 46 6576–6591. (doi:10.1093/nar/gky449)
Barclay JL, Anderson ST, Waters MJ & Curlewis JD 2007 Regulation of Suppressor of
Cytokine Signaling 3 (SOC3) by Growth Hormone in Pro-B Cells. Molecular
Endocrinology 21 2503–2515. (doi:10.1210/me.2006-0498)
Barski A, Cuddapah S, Cui K, Roh T-Y, Schones DE, Wang Z, Wei G, Chepelev I & Zhao
K 2007 High-Resolution Profiling of Histone Methylations in the Human Genome.
Cell 129 823–837. (doi:10.1016/j.cell.2007.05.009)
Berghe W Vanden, Vermeulen L, De Wilde G, De Bosscher K, Boone E & Haegeman G
2000 Signal transduction by tumor necrosis factor and gene regulation of the
inflammatory cytokine interleukin-6. Biochemical Pharmacology 60 1185–1195.
82

(doi:10.1016/S0006-2952(00)00412-3)
Boden G 1999 Free Fatty Acids, Insulin Resistance, and Type 2 Diabetes Mellitus.
Proceedings of The Association of American Physicians 111 241–248.
(doi:10.1046/j.1525-1381.1999.99220.x)
Bruun JM, Lihn AS, Pedersen SB & Richelsen B 2005 Monocyte Chemoattractant
Protein-1 Release Is Higher in Visceral than Subcutaneous Human Adipose Tissue
(AT): Implication of Macrophages Resident in the AT. The Journal of Clinical
Endocrinology & Metabolism 90 2282–2289. (doi:10.1210/jc.2004-1696)
Carvalho E, Kotani K, Peroni OD & Kahn BB 2005 Adipose-specific overexpression of
GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively
in muscle. American Journal of Physiology-Endocrinology and Metabolism 289
E551–E561. (doi:10.1152/ajpendo.00116.2005)
Casciello F, Windloch K, Gannon F & Lee JS 2015 Functional Role of G9a Histone
Methyltransferase
in
Cancer.
Frontiers
in
Immunology
6
487.
(doi:10.3389/fimmu.2015.00487)
Castaño C, Kalko S, Novials A & Párrizas M 2018 Obesity-associated exosomal miRNAs
modulate glucose and lipid metabolism in mice. Proceedings of the National
Academy of Sciences of the United States of America 115 12158–12163.
(doi:10.1073/pnas.1808855115)
Cawthorn WP & Sethi JK 2008 TNF-alpha and adipocyte biology. FEBS Letters 582 117–
131. (doi:10.1016/j.febslet.2007.11.051)
Chao LC & Tontonoz P 2012 SIRT1 Regulation—It Ain’t All NAD. Molecular Cell 45 9–
11. (doi:10.1016/j.molcel.2011.12.017)
Chaturvedi C-P, Hosey AM, Palii C, Perez-Iratxeta C, Nakatani Y, Ranish JA, Dilworth FJ
& Brand M 2009 Dual role for the methyltransferase G9a in the maintenance of globin gene transcription in adult erythroid cells. Proceedings of the National
Academy of Sciences 106 18303–18308. (doi:10.1073/pnas.0906769106)
Chen H, Yan Y, Davidson TL, Shinkai Y & Costa M 2006 Hypoxic Stress Induces
Dimethylated Histone H3 Lysine 9 through Histone Methyltransferase G9a in
Mammalian Cells. Cancer Research 66 9009–9016. (doi:10.1158/0008-5472.CAN06-0101)
Chin H, Nakamura N, Kamiyama R, Miyasaka N, Ihle JN & Miura O 1996 Physical and
functional interactions between Stat5 and the tyrosine- phosphorylated receptors for
erythropoietin and interleukin-3. Blood 88 4415–4425.
Chin HG, Estève P-O, Pradhan M, Benner J, Patnaik D, Carey MF & Pradhan S 2007
Automethylation of G9a and its implication in wider substrate specificity and HP1
binding. Nucleic Acids Research 35 7313–7323. (doi:10.1093/nar/gkm726)
Chini CCS, Escande C, Nin V & Chini EN 2010 HDAC3 Is Negatively Regulated by the
Nuclear Protein DBC1. Journal of Biological Chemistry 285 40830–40837.
(doi:10.1074/jbc.M110.153270)
83

Chini CCS, Escande C, Nin V & Chini EN 2013 DBC1 (Deleted in Breast Cancer 1)
modulates the stability and function of the nuclear receptor Rev-erbα. The
Biochemical Journal 451 453–461. (doi:10.1042/BJ20121085)
Chusyd DE, Wang D, Huffman DM & Nagy TR 2016 Relationships between Rodent White
Adipose Fat Pads and Human White Adipose Fat Depots. Frontiers in Nutrition 3 10.
(doi:10.3389/fnut.2016.00010)
Collins RE, Northrop JP, Horton JR, Lee DY, Zhang X, Stallcup MR & Cheng X 2008 The
ankyrin repeats of G9a and GLP histone methyltransferases are mono- and
dimethyllysine binding modules. Nature Structural & Molecular Biology 15 245–250.
(doi:10.1038/nsmb.1384)
Coulter AA & Stephens JM 2006 STAT5 activators modulate acyl CoA oxidase (AOX)
expression in adipocytes and STAT5A binds to the AOX promoter in vitro.
Biochemical and Biophysical Research Communications 344 1342–1345.
(doi:10.1016/j.bbrc.2006.04.071)
Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL,
Tseng Y-H, Doria A et al. 2009 Identification and Importance of Brown Adipose
Tissue in Adult Humans. New England Journal of Medicine 360 1509–1517.
(doi:10.1056/NEJMoa0810780)
Degawa-Yamauchi M, Moss KA, Bovenkerk JE, Shankar SS, Morrison CL, Lelliott CJ,
Vidal-Puig A, Jones R & Considine R V. 2005 Regulation of Adiponectin Expression
in Human Adipocytes: Effects of Adiposity, Glucocorticoids, and Tumor Necrosis
Factor α. Obesity Research 13 662–669. (doi:10.1038/oby.2005.74)
Ea C-K, Hao S, Yeo KS & Baltimore D 2012 EHMT1 Protein Binds to Nuclear Factor-κB
p50 and Represses Gene Expression. The Journal of Biological Chemistry 287
31207. (doi:10.1074/JBC.M112.365601)
Escande C, Chini CCS, Nin V, Dykhouse KM, Novak CM, Levine J, van Deursen J, Gores
GJ, Chen J, Lou Z et al. 2010 Deleted in breast cancer–1 regulates SIRT1 activity
and contributes to high-fat diet–induced liver steatosis in mice. Journal of Clinical
Investigation 120 545–558. (doi:10.1172/JCI39319)
Escande C, Nin V, Pirtskhalava T, Chini CC, Thereza Barbosa M, Mathison A, Urrutia R,
Tchkonia T, Kirkland JL & Chini EN 2014 Deleted in Breast Cancer 1 regulates
cellular
senescence
during
obesity.
Aging
Cell
13
951–953.
(doi:10.1111/acel.12235)
Escande C, Nin V, Pirtskhalava T, Chini CCS, Tchkonia T, Kirkland JL & Chini EN 2015
Deleted in breast cancer 1 limits adipose tissue fat accumulation and plays a key role
in the development of metabolic syndrome phenotype. Diabetes 64 12–22.
(doi:10.2337/db14-0192)
Ezaki O 1989 Mechanism for increased insulin-stimulated glucose metabolism in
adipocytes from 13-week-old obese Zucker rats. Diabetologia 32 290–294.
(doi:10.1007/BF00265544)
84

Fain JN, Madan AK, Hiler ML, Cheema P & Bahouth SW 2004 Comparison of the Release
of Adipokines by Adipose Tissue, Adipose Tissue Matrix, and Adipocytes from
Visceral and Subcutaneous Abdominal Adipose Tissues of Obese Humans.
Endocrinology 145 2273–2282. (doi:10.1210/en.2003-1336)
Fasshauer M, Klein J, Neumann S, Eszlinger M & Paschke R 2002 Hormonal Regulation
of Adiponectin Gene Expression in 3T3-L1 Adipocytes. Biochemical and Biophysical
Research Communications 290 1084–1089. (doi:10.1006/bbrc.2001.6307)
Feinstein R, Kanety H, Papa MZ, Lunenfeld B & Karasik A 1993 Tumor necrosis factoralpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its
substrates. The Journal of Biological Chemistry 268 26055–26058.
Fiszbein A, Giono LE, Quaglino A, Berardino BG, Sigaut L, von Bilderling C, Schor IE,
Steinberg JHE, Rossi M, Pietrasanta LI et al. 2016 Alternative Splicing of G9a
Regulates
Neuronal
Differentiation.
Cell
Reports
14
2797–2808.
(doi:10.1016/J.CELREP.2016.02.063)
Floyd ZE & Stephens JM 2003a STAT5A promotes adipogenesis in nonprecursor cells
and associates with the glucocorticoid receptor during adipocyte differentiation.
Diabetes 52 308–314. (doi:10.2337/diabetes.52.2.308)
Floyd ZE & Stephens JM 2003b STAT5A promotes adipogenesis in nonprecursor cells
and associates with the glucocorticoid receptor during adipocyte differentiation.
Diabetes 52 308–314.
Floyd ZE, Segura BM, He F & Stephens JM 2007 Degradation of STAT5 proteins in 3T3L1 adipocytes is induced by TNF-α and cycloheximide in a manner independent of
STAT5A activation. American Journal of Physiology-Endocrinology and Metabolism
292 E461–E468. (doi:10.1152/ajpendo.00334.2006)
Frayn KN, Arner P & Yki-Järvinen H 2006 Fatty acid metabolism in adipose tissue, muscle
and liver in health and disease. Essays In Biochemistry 42 89–103.
(doi:10.1042/bse0420089)
Fritsch L, Robin P, Mathieu JRR, Souidi M, Hinaux H, Rougeulle C, Harel-Bellan A,
Ameyar-Zazoua M & Ait-Si-Ali S 2010 A Subset of the Histone H3 Lysine 9
Methyltransferases Suv39h1, G9a, GLP, and SETDB1 Participate in a Multimeric
Complex. Molecular Cell 37 46–56. (doi:10.1016/j.molcel.2009.12.017)
Fu Y, Luo N, Klein RL & Garvey WT 2005 Adiponectin promotes adipocyte differentiation,
insulin sensitivity, and lipid accumulation. Journal of Lipid Research 46 1369–1379.
(doi:10.1194/jlr.M400373-JLR200)
Fu J, Jiang J, Li J, Wang S, Shi G, Feng Q, White E, Qin J & Wong J 2009 Deleted in
breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNAbinding activity. The Journal of Biological Chemistry 284 6832–6840.
(doi:10.1074/jbc.M808988200)
Gadde KM, Martin CK, Berthoud H-R & Heymsfield SB 2018 Obesity. Journal of the
American College of Cardiology 71 69–84. (doi:10.1016/j.jacc.2017.11.011)
85

Green A, Rumberger JM, Stuart CA & Ruhoff MS 2004 Stimulation of Lipolysis by Tumor
Necrosis Factor- in 3T3-L1 Adipocytes Is Glucose Dependent: Implications for LongTerm Regulation of Lipolysis. Diabetes 53 74–81. (doi:10.2337/diabetes.53.1.74)
Győry I, Wu J, Fejér G, Seto E & Wright KL 2004 PRDI-BF1 recruits the histone H3
methyltransferase G9a in transcriptional silencing. Nature Immunology 5 299–308.
(doi:10.1038/ni1046)
Halaas J, Gajiwala K, Maffei M, Cohen S, Chait B, Rabinowitz D, Lallone R, Burley S &
Friedman J 1995 Weight-reducing effects of the plasma protein encoded by the
obese gene. Science 269 543–546. (doi:10.1126/science.7624777)
Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L, Walsh T, Welcsh
P, King M-C & Wigler MH 2002 DBC2, a candidate for a tumor suppressor gene
involved in breast cancer. Proceedings of the National Academy of Sciences of the
United States of America 99 13647–13652. (doi:10.1073/pnas.212516099)
Harp JB, Franklin D, Vanderpuije AA & Gimble JM 2001 Differential Expression of Signal
Transducers and Activators of Transcription during Human Adipogenesis.
Biochemical and Biophysical Research Communications 281 907–912.
(doi:10.1006/bbrc.2001.4460)
Harrison DA, McCoon PE, Binari R, Gilman M & Perrimon N 1998 Drosophila unpaired
encodes a secreted protein that activates the JAK signaling pathway. Genes and
Development 12 3252–3263. (doi:10.1101/gad.12.20.3252)
He Y, Lu L, Wei X, Jin D, Qian T, Yu A, Sun J, Cui J & Yang Z 2016 The multimerization
and secretion of adiponectin are regulated by TNF-alpha. Endocrine 51 456–468.
(doi:10.1007/s12020-015-0741-4)
Herz H-M, Garruss A & Shilatifard A 2013 SET for life: biochemical activities and
biological functions of SET domain-containing proteins. Trends in Biochemical
Sciences 38 621–639. (doi:10.1016/j.tibs.2013.09.004)
Hiraike H, Wada-Hiraike O, Nakagawa S, Koyama S, Miyamoto Y, Sone K, Tanikawa M,
Tsuruga T, Nagasaka K, Matsumoto Y et al. 2010 Identification of DBC1 as a
transcriptional repressor for BRCA1. British Journal of Cancer 102 1061–1067.
(doi:10.1038/sj.bjc.6605577)
Hogan JC & Stephens JM 2005 The regulation of fatty acid synthase by STAT5A.
Diabetes 54 1968–1975. (doi:10.2337/DIABETES.54.7.1968)
Hotamisligil GS, Murray DL, Choy LN & Spiegelman BM 1994 Tumor necrosis factor
alpha inhibits signaling from the insulin receptor. Proceedings of the National
Academy of Sciences 91 4854–4858. (doi:10.1073/pnas.91.11.4854)
Hotamisligil GS, Arner P, Caro JF, Atkinson RL & Spiegelman BM 1995 Increased
adipose tissue expression of tumor necrosis factor-alpha in human obesity and
insulin resistance. Journal of Clinical Investigation 95 2409–2415.
(doi:10.1172/JCI117936)
Hu E, Liang P & Spiegelman BM 1996 AdipoQ Is a Novel Adipose-specific Gene
86

Dysregulated in Obesity. Journal of Biological Chemistry 271 10697–10703.
(doi:10.1074/jbc.271.18.10697)
Huang J, Dorsey J, Chuikov S, Pérez-Burgos L, Zhang X, Jenuwein T, Reinberg D &
Berger SL 2010 G9a and Glp methylate lysine 373 in the tumor suppressor p53. The
Journal of Biological Chemistry 285 9636–9641. (doi:10.1074/jbc.M109.062588)
Ikeda K, Maretich P & Kajimura S 2018 The Common and Distinct Features of Brown and
Beige Adipocytes. Trends in Endocrinology & Metabolism 29 191–200.
(doi:10.1016/J.TEM.2018.01.001)
Inagawa M, Nakajima K, Makino T, Ogawa S, Kojima M, Ito S, Ikenishi A, Hayashi T,
Schwartz RJ, Nakamura K et al. 2013 Histone H3 lysine 9 methyltransferases, G9a
and GLP are essential for cardiac morphogenesis. Mechanisms of Development 130
519–531. (doi:10.1016/j.mod.2013.07.002)
Joshi P, Quach OL, Giguere SSB & Cristea IM 2013 A Functional Proteomics Perspective
of DBC1 as a Regulator of Transcription. Journal of Proteomics & Bioinformatics
Suppl 2.
Karlsson H, Gustafsson J-Å & Mode A 1999 Cis desensitizes GH induced Stat5 signaling
in rat liver cells. Molecular and Cellular Endocrinology 154 37–43.
(doi:10.1016/S0303-7207(99)00101-X)
Kim E-J, Kho J-H, Kang M-R & Um S-J 2007 Active Regulator of SIRT1 Cooperates with
SIRT1 and Facilitates Suppression of p53 Activity. Molecular Cell 28 277–290.
(doi:10.1016/j.molcel.2007.08.030)
Kim J-E, Chen J & Lou Z 2008 DBC1 is a negative regulator of SIRT1. Nature 451 583–
586. (doi:10.1038/nature06500)
Kim Y, Lee H-M, Xiong Y, Sciaky N, Hulbert SW, Cao X, Everitt JI, Jin J, Roth BL & Jiang
Y 2017 Targeting the histone methyltransferase G9a activates imprinted genes and
improves survival of a mouse model of Prader–Willi syndrome. Nature Medicine 23
213–222. (doi:10.1038/nm.4257)
Kong S, Dong H, Song J, Thiruppathi M, Prabhakar BS, Qiu Q, Lin Z, Chini E, Zhang B
& Fang D 2015 Deleted in Breast Cancer 1 Suppresses B Cell Activation through
RelB and Is Regulated by IKKα Phosphorylation. Journal of Immunology (Baltimore,
Md. : 1950) 195 3685–3693. (doi:10.4049/jimmunol.1500713)
Koyama S, Wada-Hiraike O, Nakagawa S, Tanikawa M, Hiraike H, Miyamoto Y, Sone K,
Oda K, Fukuhara H, Nakagawa K et al. 2010 Repression of estrogen receptor β
function by putative tumor suppressor DBC1. Biochemical and Biophysical Research
Communications 392 357–362. (doi:10.1016/j.bbrc.2010.01.025)
Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M & Fasshauer M 2005a
Isoproterenol, TNFα, and insulin downregulate adipose triglyceride lipase in 3T3-L1
adipocytes.
Molecular
and
Cellular
Endocrinology
240
43–49.
(doi:10.1016/j.mce.2005.06.002)
Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M & Fasshauer M 2005b
87

Isoproterenol, TNFα, and insulin downregulate adipose triglyceride lipase in 3T3-L1
adipocytes.
Molecular
and
Cellular
Endocrinology
240
43–49.
(doi:10.1016/j.mce.2005.06.002)
Kwon H, Kim D & Kim JS 2017 Body Fat Distribution and the Risk of Incident Metabolic
Syndrome: A Longitudinal Cohort Study. Scientific Reports 7 10955.
(doi:10.1038/s41598-017-09723-y)
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F & Straif K 2016 Body
Fatness and Cancer — Viewpoint of the IARC Working Group. New England Journal
of Medicine 375 794–798. (doi:10.1056/NEJMsr1606602)
Laurencikiene J, Van Harmelen V, Nordström EA, Dicker A, Blomqvist L, Näslund E,
Langin D, Arner P & Rydén M 2007 NF-kB is important for TNF-a-induced lipolysis
in human adipocytes. J. Lipid Res 48 1069–1077. (doi:10.1194/jlr.M600471-JLR200)
Lee DY, Northrop JP, Kuo M-H & Stallcup MR 2006 Histone H3 Lysine 9
Methyltransferase G9a Is a Transcriptional Coactivator for Nuclear Receptors.
Journal of Biological Chemistry 281 8476–8485. (doi:10.1074/jbc.M511093200)
Lee KY, Sharma R, Gase G, Ussar S, Li Y, Welch L, Berryman DE, Kispert A, Bluher M
& Kahn CR 2017 Tbx15 Defines a Glycolytic Subpopulation and White Adipocyte
Heterogeneity. Diabetes 66 2822–2829. (doi:10.2337/db17-0218)
Lee KY, Luong Q, Sharma R, Dreyfuss JM, Ussar S & Kahn CR 2019 Developmental and
functional heterogeneity of white adipocytes within a single fat depot. The EMBO
Journal 38. (doi:10.15252/embj.201899291)
Li Z, Chen L, Kabra N, Wang C, Fang J & Chen J 2009 Inhibition of SUV39H1
Methyltransferase Activity by DBC1. Journal of Biological Chemistry 284 10361–
10366. (doi:10.1074/jbc.M900956200)
Libermann TA & Baltimore D 1990 Activation of interleukin-6 gene expression through
the NF-kappa B transcription factor. Molecular and Cellular Biology 10 2327–2334.
Lin G, LaPensee CR, Qin ZS & Schwartz J 2014 Reciprocal occupancy of BCL6 and
STAT5 on Growth Hormone target genes: contrasting transcriptional outcomes and
promoter-specific roles of p300 and HDAC3. Molecular and Cellular Endocrinology
395 19–31. (doi:10.1016/j.mce.2014.07.020)
Liu C, Yu Y, Liu F, Wei X, Wrobel JA, Gunawardena HP, Zhou L, Jin J & Chen X 2014 A
chromatin activity-based chemoproteomic approach reveals a transcriptional
repressome for gene-specific silencing. Nature Communications 5 5733.
(doi:10.1038/ncomms6733)
Liu N, Zhang Z, Wu H, Jiang Y, Meng L, Xiong J, Zhao Z, Zhou X, Li J, Li H et al. 2015
Recognition of H3K9 methylation by GLP is required for efficient establishment of
H3K9 methylation, rapid target gene repression, and mouse viability. Genes &
Development 29 379–393. (doi:10.1101/gad.254425.114)
Liu X, Ehmed E, Li B, Dou J, Qiao X, Jiang W, Yang X, Qiao S & Wu Y 2016 Breast
cancer metastasis suppressor 1 modulates SIRT1-dependent p53 deacetylation
88

through interacting with DBC1. American Journal of Cancer Research 6 1441–1449.
Lu T & Stark GR 2015 NF-κB: Regulation by Methylation. Cancer Research 75 3692–
3695. (doi:10.1158/0008-5472.CAN-15-1022)
Lumeng CN, Deyoung SM, Bodzin JL & Saltiel AR 2007 Increased inflammatory
properties of adipose tissue macrophages recruited during diet-induced obesity.
Diabetes 56 16–23. (doi:10.2337/db06-1076)
Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y & Matsubara K 1996 cDNA
Cloning and Expression of a Novel Adipose Specific Collagen-like Factor, apM1
(AdiposeMost Abundant Gene Transcript 1). Biochemical and Biophysical Research
Communications 221 286–289. (doi:10.1006/bbrc.1996.0587)
Mandal SS 2017 Gene Regulation, Epigenetics and Hormone Signaling. Weinheim,
Germany: Wiley-VCH Verlag GmbH & Co. KGaA. (doi:10.1002/9783527697274)
Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A &
Yoshimura A 1997 CIS, a cytokine inducible SH2 protein, is a target of the JAKSTAT5 pathway and modulates STAT5 activation. Blood 89 3148–3154.
Moore KE, Carlson SM, Camp ND, Cheung P, James RG, Chua KF, Wolf-Yadlin A &
Gozani O 2013 A general molecular affinity strategy for global detection and
proteomic analysis of lysine methylation. Molecular Cell 50 444–456.
(doi:10.1016/j.molcel.2013.03.005)
Moreno-Navarrete JM, Moreno M, Vidal M, Ortega F, Serrano M, Xifra G, Ricart W &
Fernández-Real JM 2015a Deleted in breast cancer 1 plays a functional role in
adipocyte differentiation. American Journal of Physiology - Endocrinology And
Metabolism 308 E554–E561. (doi:10.1152/ajpendo.00286.2014)
Moreno-Navarrete JM, Moreno M, Vidal M, Ortega F, Ricart W & Fernández-Real JM
2015b DBC1 is involved in adipocyte inflammation and is a possible marker of human
adipose tissue senescence. Obesity 23 519–522. (doi:10.1002/oby.20999)
Mori MA, Raghavan P, Thomou T, Boucher J, Robida-Stubbs S, Macotela Y, Russell SJ,
Kirkland JL, Blackwell TK & Kahn CR 2012 Role of microRNA processing in adipose
tissue in stress defense and longevity. Cell Metabolism 16 336–347.
(doi:10.1016/j.cmet.2012.07.017)
Mullen M & Gonzalez-Perez R 2016 Leptin-Induced JAK/STAT Signaling and Cancer
Growth. Vaccines 4 26. (doi:10.3390/vaccines4030026)
Nedergaard J, Golozoubova V, Matthias A, Asadi A, Jacobsson A & Cannon B 2001
UCP1: the only protein able to mediate adaptive non-shivering thermogenesis and
metabolic inefficiency. Biochimica et Biophysica Acta 1504 82–106.
(doi:10.1016/s0005-2728(00)00247-4)
Nedergaard J, Bengtsson T & Cannon B 2007 Unexpected evidence for active brown
adipose tissue in adult humans. American Journal of Physiology-Endocrinology and
Metabolism 293 E444–E452. (doi:10.1152/ajpendo.00691.2006)
89

Nin V, Chini CCS, Escande C, Capellini V & Chini EN 2014 Deleted in breast cancer 1
(DBC1) protein regulates hepatic gluconeogenesis. The Journal of Biological
Chemistry 289 5518–5527. (doi:10.1074/jbc.M113.512913)
Nishio H & Walsh MJ 2004 CCAAT displacement protein/cut homolog recruits G9a
histone lysine methyltransferase to repress transcription. Proceedings of the National
Academy of Sciences 101 11257–11262. (doi:10.1073/pnas.0401343101)
Nov O, Shapiro H, Ovadia H, Tarnovscki T, Dvir I, Shemesh E, Kovsan J, Shelef I, Carmi
Y, Voronov E et al. 2013 Interleukin-1β Regulates Fat-Liver Crosstalk in Obesity by
Auto-Paracrine Modulation of Adipose Tissue Inflammation and Expandability. PLoS
ONE 8 e53626. (doi:10.1371/journal.pone.0053626)
Oh S-T, Kim K-B, Chae Y-C, Kang J-Y, Hahn Y & Seo S-B 2014 H3K9 histone
methyltransferase G9a-mediated transcriptional activation of p21. FEBS Letters 588
685–691. (doi:10.1016/j.febslet.2014.01.039)
Ohno H, Shinoda K, Ohyama K, Sharp LZ & Kajimura S 2013 EHMT1 controls brown
adipose cell fate and thermogenesis through the PRDM16 complex. Nature 504 163–
167. (doi:10.1038/nature12652)
Ouchi N & Walsh K 2007 Adiponectin as an anti-inflammatory factor. Clinica Chimica Acta
380 24–30. (doi:10.1016/j.cca.2007.01.026)
Peters AHFM, Kubicek S, Mechtler K, O’Sullivan RJ, Derijck AAHA, Perez-Burgos L,
Kohlmaier A, Opravil S, Tachibana M, Shinkai Y et al. 2003 Partitioning and plasticity
of repressive histone methylation states in mammalian chromatin. Molecular Cell 12
1577–1589.
Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M & Tschop MH 2008 Sirt1 protects
against high-fat diet-induced metabolic damage. Proceedings of the National
Academy of Sciences 105 9793–9798. (doi:10.1073/pnas.0802917105)
Ping D, Boekhoudt GH, Rogers EM & Boss JM 1999 Nuclear factor-kappa B p65
mediates the assembly and activation of the TNF-responsive element of the murine
monocyte chemoattractant-1 gene. Journal of Immunology (Baltimore, Md. : 1950)
162 727–734.
Pless O, Kowenz-Leutz E, Knoblich M, Lausen J, Beyermann M, Walsh MJ & Leutz A
2008 G9a-mediated lysine methylation alters the function of CCAAT/enhancerbinding protein-beta. The Journal of Biological Chemistry 283 26357–26363.
(doi:10.1074/jbc.M802132200)
Poulard C, Bittencourt D, Wu D, Hu Y, Gerke DS & Stallcup MR 2017 A post‐translational
modification switch controls coactivator function of histone methyltransferases G9a
and GLP. EMBO Reports 18 1442–1459. (doi:10.15252/embr.201744060)
Purcell DJ, Jeong KW, Bittencourt D, Gerke DS & Stallcup MR 2011 A Distinct
Mechanism for Coactivator versus Corepressor Function by Histone
Methyltransferase G9a in Transcriptional Regulation. Journal of Biological Chemistry
286 41963–41971. (doi:10.1074/jbc.M111.298463)
90

Purcell DJ, Khalid O, Ou C-Y, Little GH, Frenkel B, Baniwal SK & Stallcup MR 2012
Recruitment of coregulator G9a by Runx2 for selective enhancement or suppression
of transcription. Journal of Cellular Biochemistry 113 2406–2414.
(doi:10.1002/jcb.24114)
Qatanani M, Szwergold NR, Greaves DR, Ahima RS & Lazar MA 2009 Macrophagederived human resistin exacerbates adipose tissue inflammation and insulin
resistance in mice. The Journal of Clinical Investigation 119 531–539.
(doi:10.1172/JCI37273)
Rada M, Vasileva E, Lezina L, Marouco D, Antonov A V, Macip S, Melino G & Barlev NA
2017 Human EHMT2/G9a activates p53 through methylation-independent
mechanism. Oncogene 36 922–932. (doi:10.1038/onc.2016.258)
Rahman S & Islam R 2011 Mammalian Sirt1: insights on its biological functions. Cell
Communication and Signaling 9 11. (doi:10.1186/1478-811X-9-11)
Rajala MW & Scherer PE 2003 Minireview: The Adipocyte—At the Crossroads of Energy
Homeostasis, Inflammation, and Atherosclerosis. Endocrinology 144 3765–3773.
(doi:10.1210/en.2003-0580)
Rao VK, Pal A & Taneja R 2017 A drive in SUVs: From development to disease.
Epigenetics 12 177–186. (doi:10.1080/15592294.2017.1281502)
Rathert P, Dhayalan A, Murakami M, Zhang X, Tamas R, Jurkowska R, Komatsu Y,
Shinkai Y, Cheng X & Jeltsch A 2008 Protein lysine methyltransferase G9a acts on
non-histone
targets.
Nature
Chemical
Biology
4
344–346.
(doi:10.1038/nchembio.88)
Rawlings JS, Rosler KM & Harrison DA 2004 The JAK/STAT signaling pathway. Journal
of Cell Science 117. (doi:10.1242/jcs.00963)
Rea S, Eisenhaber F, O’Carroll D, Strahl BD, Sun Z-W, Schmid M, Opravil S, Mechtler K,
Ponting CP, Allis CD et al. 2000 Regulation of chromatin structure by site-specific
histone H3 methyltransferases. Nature 406 593–599. (doi:10.1038/35020506)
Richard AJ, Hang H & Stephens JM 2017 Pyruvate dehydrogenase complex (PDC)
subunits moonlight as interaction partners of phosphorylated STAT5 in adipocytes
and adipose tissue. The Journal of Biological Chemistry 292 19733–19742.
(doi:10.1074/jbc.M117.811794)
Richter HE, Albrektsen T & Billestrup N 2003 The role of signal transducer and activator
of transcription 5 in the inhibitory effects of GH on adipocyte differentiation. Journal
of Molecular Endocrinology 30 139–150.
Rosen ED & Spiegelman BM 2006 Adipocytes as regulators of energy balance and
glucose homeostasis. Nature 444 847–853. (doi:10.1038/nature05483)
Rosen ED & Spiegelman BM 2014 What we talk about when we talk about fat. Cell 156
20–44. (doi:10.1016/j.cell.2013.12.012)
Ruan H & Dong LQ 2016 Adiponectin signaling and function in insulin target tissues.
91

Journal of Molecular Cell Biology 8 101–109. (doi:10.1093/jmcb/mjw014)
Ruan H, Hacohen N, Golub TR, Van Parijs L & Lodish HF 2002a Tumor necrosis factoralpha suppresses adipocyte-specific genes and activates expression of preadipocyte
genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is
obligatory. Diabetes 51 1319–1336.
Ruan H, Miles PDG, Ladd CM, Ross K, Golub TR, Olefsky JM & Lodish HF 2002b
Profiling gene transcription in vivo reveals adipose tissue as an immediate target of
tumor necrosis factor-alpha: implications for insulin resistance. Diabetes 51 3176–
3188.
Ruan H, Hacohen N, Golub TR, Van Parijs L & Lodish HF 2002c Tumor necrosis factoralpha suppresses adipocyte-specific genes and activates expression of preadipocyte
genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is
obligatory. Diabetes 51 1319–1336. (doi:10.2337/DIABETES.51.5.1319)
Rydén M, Arvidsson E, Blomqvist L, Perbeck L, Dicker A & Arner P 2004 Targets for TNFα-induced lipolysis in human adipocytes. Biochemical and Biophysical Research
Communications 318 168–175. (doi:10.1016/J.BBRC.2004.04.010)
Saltiel AR & Olefsky JM 2017 Inflammatory mechanisms linking obesity and metabolic
disease. The Journal of Clinical Investigation 127 1. (doi:10.1172/JCI92035)
Samocha-Bonet D, Dixit VD, Kahn CR, Leibel RL, Lin X, Nieuwdorp M, Pietiläinen KH,
Rabasa-Lhoret R, Roden M, Scherer PE et al. 2014 Metabolically healthy and
unhealthy obese – the 2013 Stock Conference report HHS Public Access. Obes Rev
15 697–708. (doi:10.1111/obr.12199)
Scheja L & Heeren J 2019 The endocrine function of adipose tissues in health and
cardiometabolic disease. Nature Reviews Endocrinology 15 507–524.
(doi:10.1038/s41574-019-0230-6)
Scherer PE, Williams S, Fogliano M, Baldini G & Lodish HF 1995 A novel serum protein
similar to C1q, produced exclusively in adipocytes. The Journal of Biological
Chemistry 270 26746–26749. (doi:10.1074/jbc.270.45.26746)
Schwartz DR & Lazar MA 2011 Human resistin: found in translation from mouse to man.
Trends
in
Endocrinology
and
Metabolism:
TEM
22
259–265.
(doi:10.1016/j.tem.2011.03.005)
Shinkai Y & Tachibana M 2011 H3K9 methyltransferase G9a and the related molecule
GLP. Genes & Development 25 781–788. (doi:10.1101/gad.2027411)
Stefan N, Häring H-U, Hu FB & Schulze MB 2013 Metabolically healthy obesity:
epidemiology, mechanisms, and clinical implications. The Lancet. Diabetes &
Endocrinology 1 152–162. (doi:10.1016/S2213-8587(13)70062-7)
Stephens JM & Pekala PH 1991 Transcriptional repression of the GLUT4 and C/EBP
genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. The Journal of Biological
Chemistry 266 21839–21845.
92

Stephens JM, Morrison RF & Pilch PF 1996 The Expression and Regulation of STATs
during 3T3-L1 Adipocyte Differentiation. Journal of Biological Chemistry 271 10441–
10444. (doi:10.1074/jbc.271.18.10441)
Stephens JM, Lee J & Pilch PF 1997 Tumor necrosis factor-alpha-induced insulin
resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor
substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal
transduction. The Journal of Biological Chemistry 272 971–976.
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima
RS & Lazar MA 2001 The hormone resistin links obesity to diabetes. Nature 409
307–312. (doi:10.1038/35053000)
Stewart WC, Baugh JE, Floyd ZE & Stephens JM 2004 STAT 5 activators can replace
the requirement of FBS in the adipogenesis of 3T3-L1 cells. Biochemical and
Biophysical
Research
Communications
324
355–359.
(doi:10.1016/J.BBRC.2004.09.053)
Stewart WC, Pearcy LA, Floyd ZE & Stephens JM 2011a STAT5A Expression in Swiss
3T3 Cells Promotes Adipogenesis In Vivo in an Athymic Mice Model System. Obesity
19 1731–1734. (doi:10.1038/oby.2011.66)
Stewart WC, Pearcy LA, Floyd ZE & Stephens JM 2011b STAT5A expression in Swiss
3T3 cells promotes adipogenesis in vivo in an athymic mice model system. Obesity
(Silver Spring, Md.) 19 1731–1734. (doi:10.1038/oby.2011.66)
Story DJ & Stephens JM 2006 Modulation and Lack of Cross-Talk between Signal
Transducer and Activator of Transcription 5 and Suppressor of Cytokine Signaling-3
in Insulin and Growth Hormone Signaling in 3T3-L1 Adipocytes*. Obesity 14 1303–
1311. (doi:10.1038/oby.2006.148)
Syed I, Lee J, Moraes-Vieira PM, Donaldson CJ, Sontheimer A, Aryal P, Wellenstein K,
Kolar MJ, Nelson AT, Siegel D et al. 2018 Palmitic Acid Hydroxystearic Acids
Activate GPR40, Which Is Involved in Their Beneficial Effects on Glucose
Homeostasis. Cell Metabolism 27 419–427.e4. (doi:10.1016/j.cmet.2018.01.001)
Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, Fukuda M, Takeda N,
Niida H, Kato H et al. 2002 G9a histone methyltransferase plays a dominant role in
euchromatic histone H3 lysine 9 methylation and is essential for early
embryogenesis. Genes & Development 16 1779–1791. (doi:10.1101/gad.989402)
Tachibana M, Ueda J, Fukuda M, Takeda N, Ohta T, Iwanari H, Sakihama T, Kodama T,
Hamakubo T & Shinkai Y 2005 Histone methyltransferases G9a and GLP form
heteromeric complexes and are both crucial for methylation of euchromatin at H3K9. Genes & Development 19 815–826. (doi:10.1101/gad.1284005)
Tachibana M, Matsumura Y, Fukuda M, Kimura H & Shinkai Y 2008 G9a/GLP complexes
independently mediate H3K9 and DNA methylation to silence transcription. The
EMBO Journal 27 2681–2690. (doi:10.1038/emboj.2008.192)
Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M,
93

Bodner S, Grosveld G & Ihle JN 1998 Stat5a and Stat5b Proteins Have Essential
and Nonessential, or Redundant, Roles in Cytokine Responses. Cell 93 841–850.
(doi:10.1016/S0092-8674(00)81444-0)
Thomou T, Mori MA, Dreyfuss JM, Konishi M, Sakaguchi M, Wolfrum C, Rao TN, Winnay
JN, Garcia-Martin R, Grinspoon SK et al. 2017 Adipose-derived circulating miRNAs
regulate gene expression in other tissues. Nature 542 450–455.
(doi:10.1038/nature21365)
Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, Heim MH & Stoffel M
2011 MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474 649–653.
(doi:10.1038/nature10112)
Tse MCL, Liu X, Yang S, Ye K & Chan CB 2013 Fyn regulates adipogenesis by promoting
PIKE-A/STAT5a interaction. Molecular and Cellular Biology 33 1797–1808.
(doi:10.1128/MCB.01410-12)
Ueda A, Ishigatsubo Y, Okubo T & Yoshimura T 1997 Transcriptional regulation of the
human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB
sites and NF-kappaB/Rel subunit specificity. The Journal of Biological Chemistry 272
31092–31099. (doi:10.1074/jbc.272.49.31092)
Ueda J, Tachibana M, Ikura T & Shinkai Y 2006 Zinc Finger Protein Wiz Links G9a/GLP
Histone Methyltransferases to the Co-repressor Molecule CtBP * □ S.
(doi:10.1074/jbc.M603087200)
Varlamov O, Chu M, Cornea A, Sampath H & Roberts CT 2015 Cell-Autonomous
Heterogeneity of Nutrient Uptake in White Adipose Tissue of Rhesus Macaques.
Endocrinology 156 80–89. (doi:10.1210/en.2014-1699)
Villarroya F, Cereijo R, Villarroya J & Giralt M 2017 Brown adipose tissue as a secretory
organ. Nature Reviews Endocrinology 13 26–35. (doi:10.1038/nrendo.2016.136)
Wakao H, Wakao R, Oda A & Fujita H 2011 Constitutively active Stat5A and Stat5B
promote adipogenesis. Environmental Health and Preventive Medicine 16 247–252.
(doi:10.1007/s12199-010-0193-7)
Wang H, An W, Cao R, Xia L, Erdjument-Bromage H, Chatton B, Tempst P, Roeder RG
& Zhang Y 2003 mAM facilitates conversion by ESET of dimethyl to trimethyl lysine
9 of histone H3 to cause transcriptional repression. Molecular Cell 12 475–487.
Wang L, Xu S, Lee J-E, Baldridge A, Grullon S, Peng W & Ge K 2012 Histone H3K9
methyltransferase G9a represses PPARγ expression and adipogenesis. The EMBO
Journal 32 45–59. (doi:10.1038/emboj.2012.306)
Wang QA, Tao C, Gupta RK & Scherer PE 2013 Tracking adipogenesis during white
adipose tissue development, expansion and regeneration. Nature Medicine 19
1338–1344. (doi:10.1038/nm.3324)
White UA, Coulter AA, Miles TK & Stephens JM 2007 The STAT5A-Mediated Induction
of Pyruvate Dehydrogenase Kinase 4 Expression by Prolactin or Growth Hormone
in Adipocytes. Diabetes 56 1623–1629. (doi:10.2337/db06-1286)
94

White UA, Maier J, Zhao P, Richard AJ & Stephens JM 2016 The modulation of
adiponectin by STAT5-activating hormones. American Journal of Physiology.
Endocrinology and Metabolism 310 E129-36. (doi:10.1152/ajpendo.00068.2015)
Wu H, Min J, Lunin V V., Antoshenko T, Dombrovski L, Zeng H, Allali-Hassani A,
Campagna-Slater V, Vedadi M, Arrowsmith CH et al. 2010 Structural Biology of
Human
H3K9
Methyltransferases.
PLoS
ONE
5
e8570.
(doi:10.1371/journal.pone.0008570)
Xie H, Lim B & Lodish HF 2009 MicroRNAs induced during adipogenesis that accelerate
fat cell development are downregulated in obesity. Diabetes 58 1050–1057.
(doi:10.2337/db08-1299)
Xue W, Huang J, Chen H, Zhang Y, Zhu X, Li J, Zhang W, Yuan Y, Wang Y, Zheng L et
al. 2018 Histone methyltransferase G9a modulates hepatic insulin signaling via
regulating HMGA1. Biochimica et Biophysica Acta (BBA) - Molecular Basis of
Disease 1864 338–346. (doi:10.1016/J.BBADIS.2017.10.037)
Yamaoka K, Saharinen P, Pesu M, Holt VET, Silvennoinen O & O’Shea JJ 2004 The
Janus kinases (Jaks). Genome Biology 5 253. (doi:10.1186/gb-2004-5-12-253)
Yan Q-W, Yang Q, Mody N, Graham TE, Hsu C-H, Xu Z, Houstis NE, Kahn BB & Rosen
ED 2007 The Adipokine Lipocalin 2 Is Regulated by Obesity and Promotes Insulin
Resistance. Diabetes 56 2533–2540. (doi:10.2337/db07-0007)
Yang X, Zhang X, Heckmann BL, Lu X & Liu J 2011 Relative Contribution of Adipose
Triglyceride Lipase and Hormone-sensitive Lipase to Tumor Necrosis Factor-α (TNFα)-induced Lipolysis in Adipocytes. Journal of Biological Chemistry 286 40477–
40485. (doi:10.1074/jbc.M111.257923)
Yap KL & Zhou M-M 2011 Structure and mechanisms of lysine methylation recognition
by the chromodomain in gene transcription. Biochemistry 50 1966–1980.
(doi:10.1021/bi101885m)
Yore MM, Syed I, Moraes-Vieira PM, Zhang T, Herman MA, Homan EA, Patel RT, Lee J,
Chen S, Peroni OD et al. 2014 Discovery of a Class of Endogenous Mammalian
Lipids with Anti-Diabetic and Anti-inflammatory Effects. Cell 159 318–332.
(doi:10.1016/j.cell.2014.09.035)
Yu EJ, Kim S-H, Heo K, Ou C-Y, Stallcup MR & Kim JH 2011 Reciprocal roles of DBC1
and SIRT1 in regulating estrogen receptor α activity and co-activator synergy.
Nucleic Acids Research 39 6932–6943. (doi:10.1093/nar/gkr347)
Zeng W, Ball AR, Yokomori K & Yokomori K 2010 HP1: heterochromatin binding proteins
working the genome. Epigenetics 5 287–292.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L & Friedman JM 1994 Positional
cloning of the mouse obese gene and its human homologue. Nature 372 425–432.
(doi:10.1038/372425a0)
Zhang J, Wu Y, Zhang Y, Leroith D, Bernlohr DA & Chen X 2008 The role of lipocalin 2
in the regulation of inflammation in adipocytes and macrophages. Molecular
95

Endocrinology (Baltimore, Md.) 22 1416–1426. (doi:10.1210/me.2007-0420)
Zhang Q, Lenardo MJ & Baltimore D 2017 Leading Edge Review 30 Years of NF-kB: A
Blossoming of Relevance to Human Pathobiology. (doi:10.1016/j.cell.2016.12.012)
Zhao W, Kruse J-P, Tang Y, Jung SY, Qin J & Gu W 2008 Negative regulation of the
deacetylase SIRT1 by DBC1. Nature 451 587–590. (doi:10.1038/nature06515)
Zhao P, Elks CM & Stephens JM 2014 The Induction of Lipocalin-2 Protein Expression in
Vivo and in Vitro. Journal of Biological Chemistry 289 5960–5969.
(doi:10.1074/jbc.M113.532234)
Zhou P, Siegel D & Kahn BB 2019 PAHSAs enhance hepatic and systemic insulin
sensitivity through direct and indirect mechanisms The Journal of Clinical
Investigation. (doi:10.1172/JCI127092)
Zvonic S, Story DJ, Stephens JM & Mynatt RL 2003 Growth hormone, but not insulin,
activates STAT5 proteins in adipocytes in vitro and in vivo. Biochemical and
Biophysical Research Communications 302 359–362. (doi:10.1016/S0006291X(03)00179-7)

96

APPENDIX. COPYRIGHT PERMISSION
Appendix 1. Copyright permission for Chapter 2
Order Completed
Thank

you

for

your

order.

This Agreement between Ashley Able ("You") and Bioscientifica Limited ("Bioscientifica Limited")
consists of your order details and the terms and conditions provided by Bioscientifica Limited and
Copyright Clearance Center.
License number

Reference confirmation email for license number

License date

May, 29 2019

Licensed content publisher Bioscientifica Limited
Licensed content title

Journal of molecular endocrinology

Licensed content date

Jan 1, 1997

Type of use

Thesis/Dissertation

Requestor type

Academic institution

Format

Print, Electronic

Portion

chapter/article

The
requesting Ashley Able
person/organization
Title or numeric reference Loss of DBC1 (CCAR2) affects TNFα-induced lipolysis and Glut4 gene expression in murine
of the portion(s)
adipocytes
Title of the article or Loss of DBC1 (CCAR2) affects TNFα-induced lipolysis and Glut4 gene expression in murine
chapter the portion is from adipocytes
Editor of portion(s)

N/A

Author of portion(s)
Volume
of
monograph

serial

Ashley Able
or N/A

Page range of portion
Publication date of portion October 15, 2018
Rights for

Main product

Duration of use

Current edition and up to 5 years

Creation of copies for the no
disabled
With
minor
privileges

editing no

For distribution to
In
the
language(s)

United States

following Original language of publication

With incidental
promotional use

no

Lifetime unit quantity of
new product

Up to 499

Title

Loss of DBC1 (CCAR2) affects TNFα-induced lipolysis and Glut4 gene expression in murine
adipocytes

Institution name

other

97

Expected presentation
date

Aug 2019

Requestor Location

Pennington Biomedical Research Center
6400 Perkins Rd
Baton Rouge, LA 70808
United States
Attn: Pennington Biomedical Research Center

Billing Type

Invoice

Billing address

Pennington Biomedical Research Center
6400 Perkins Rd
Baton Rouge, LA 70808
United States
Attn: Ashley Able

Total (may include CCC
user fee)

0.00 USD

Total

0.00 USD

98

VITA
Ashley Ann Able was born and raised in Destrehan, Louisiana and graduated from
Destrehan High School in May 2008. In August 2008, she began her undergraduate
career and she decided to major in Biochemistry at Louisiana State University after taking
her first Biochemistry course. She received her B.S. in Biochemistry in May 2013. In
August 2015, Ashley started the PhD program at Louisiana State University. She studies
adipocyte biology in context of obesity and Type 2 diabetes in Dr. Jackie Stephens lab at
Pennington Biomedical Research Center. Ashley anticipates graduating with a Doctor of
Philosophy degree in Biochemistry in December 2019.

99

